Paclitaxel alters the function of the small diameter sensory neurons by Gracias, Neilia
  
 















Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements  
for the degree  
Doctor of Philosophy 




	   	   	   	   	   ii 
Accepted by the Faculty of Indiana University, in partial  
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
       
Michael R. Vasko, Ph.D., Chairperson 
 
 
       
Nickolay Brustovetsky, Ph.D. 
Doctoral Committee 
 
       
 Cynthia M. Hingtgen, M.D., Ph.D. 
 
 
       
Andy Hudmon, Ph.D. 
 
May 14, 2010 
       
Mark R. Kelley, Ph.D. 
	   	   	   	   	   iii 
DEDICATION 
This thesis is dedicated to my parents for their undying support and 
encouragement in my pursuit of higher education and to the extended 
Gracias family for their confidence that I can do anything.  
	   	   	   	   	   iv 
ACKNOWLEDGEMENTS 
This thesis would not be possible without the support and 
contributions of a number of people. 
I thank my mentor Dr. Michael Vasko for challenging me to think, 
for instilling in me a question-driven approach towards science, for being 
an excellent and patient teacher, for being fair and supportive even on 
days when I doubted my own potential to succeed. I attribute not only my 
success in graduate school but also my ability to succeed in future 
endeavors to several important lessons you have taught me. I thank Dr. 
Hingtgen, Dr. Hudmon, and Dr. Brustovetsky for contributing immensely to 
my scientific growth and for encouraging me to always look at the big 
picture and not just at individual experiments. I thank Dr. Brian Jarecki for 
help with experiments that were important to this thesis and for several 
interesting conversations. I thank Dr. Rajesh Khanna, Dr. Gerry Oxford, 
Dr. Ted Cummins, Dr. Grant Nicol, and other members of the sensory 
neuron group for much needed scientific advice especially when I needed 
to find solutions to challenging problems.  
My scientific growth in the last few years would not be complete 
without the support of present and past members of the Vasko lab. I thank 
Dr. Djane Duarte and Ramy Habashy for the many enlightening 
discussions we’ve had on science and non-science issues, for the fun 
times outside of work and for always providing advice when required. I 
thank Eric Thompson and Chunlu Guo for help with molecular biology and 
	   	   	   	   	   v 
other experiments, Dr. Kellie Park for advice regarding survival in 
graduate school during my early days in the Vasko lab, and the various 
work study students but most notably Joshua Taylor, Alaina Gemelas, 
Brian McCormick, Sabrina McElhannon, and Monica Wilkins for help with 
lab duties so I could focus on science.  
Several individuals outside the Vasko lab provided moral support 
over the last few years and for this I am very thankful. These are Dr. David 
Onyango, Dr. Vanina Elias, Leslie Sitzmann, and Chao Li. I wish you all 
much success in your careers. I am equally grateful to several friends 
outside of the academic environment for providing encouragement along 
the way. These are Virginia Fikry, Michelle Menezes, Christopher 
D’Souza, Dr. Evelyn Lobo, Dr. Philomena Dias, Valent D’Silva, Blaise 
D’Silva, Megan D’Silva, and Noor Baludu.  
I thank the staff at the Department of Pharmacology and Toxicology 
and the Stark Neuroscience Research Institute namely Amy Doherty, 
Nastassia Belton, Amy Lawson, Lisa King, Lisa Parks-Connell, Miriam 
Barr, and Dan Smith for all the administrative help they provided and 
continue to provide to current students.  
Lastly, I thank Arsalan Syed for being my strength in the last few 
years and especially during the thesis writing process. Your loyalty, your 
patience, your desire to see me excel in everything I undertake and your 
pride in my accomplishments kept me going and continue to boost my 
morale on a daily basis and for this I consider myself truly blessed.  
	   	   	   	   	   vi 
ABSTRACT 
Neilia Gracias 
PACLITAXEL ALTERS THE FUNCTION OF THE SMALL DIAMETER 
SENSORY NEURONS 
 
Although paclitaxel is a commonly used anti-neoplastic agent for 
the treatment of solid tumors, therapy often results in a number of side 
effects, the most debilitating of which is peripheral neuropathy. Peripheral 
neuropathy is defined as a pathology of peripheral nerves, and, depending 
on the type of nerves damaged, the neuropathy can be classified as 
sensory, motor, or autonomic neuropathy. In the case of peripheral 
neuropathy induced by paclitaxel, the symptoms are experienced in the 
extremities and are sensory in nature. Patients undergoing chemotherapy 
with paclitaxel often report sensory disturbances such as burning, tingling, 
numbness, a diminished sensation to pain and temperature, loss of 
vibration sense, loss of proprioception, and loss of deep tendon reflexes. 
Electrophysiological abnormalities including decreased sensory nerve 
action potential amplitude and conduction confirm damage to large 
myelinated fibers. However, the involvement of damage to small diameter 
sensory neurons in the etiology of paclitaxel – induced peripheral 
neuropathy is still controversial. Therefore, experiments were performed to 
determine if paclitaxel alters the function of small diameter sensory 
neurons and to examine the mechanisms responsible for the change in 
function.  
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Sensory neuron mediated vasodilatation in paclitaxel – injected 
animals was examined as an indirect measure of calcitonin gene related 
peptide (CGRP) release and therefore of sensory neuron function. CGRP 
release was also directly measured from central terminals in the spinal 
cord. To examine mechanisms of paclitaxel – induced sensory neuron 
damage, CGRP release and neurite length was examined in paclitaxel – 
treated sensory neurons in culture. The results demonstrate that (1) 
paclitaxel decreases the ability of small diameter sensory neurons to 
produce an increase in blood flow in the skin; (2) paclitaxel alters the 
release of CGRP from the small diameter sensory neurons; (3) paclitaxel 
causes the neuronal processes of isolated sensory neurons to 
degenerate. This dissertation provides novel information showing that 
paclitaxel alters the function of small diameter sensory neurons and thus 
provides a better understanding of the mechanisms mediating the sensory 
disturbances characteristic of peripheral neuropathy resulting from 
chemotherapy with paclitaxel. 
Michael R. Vasko, Ph.D, Chairperson 
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INTRODUCTION 
When the nerves that innervate peripheral tissues are damaged, 
the resulting signs and symptoms are referred to as peripheral 
neuropathy. Neuropathies are classified as autonomic, motor or sensory 
depending on the nerves affected and the symptoms experienced. 
Autonomic neuropathies result from a dysfunction of the sympathetic or 
parasympathetic nerves that regulate the function of visceral organs, 
vascular smooth muscle, endocrine and exocrine glands, the immune 
system, and soft tissues. Damage to these nerves results in impairment of 
the cardiovascular system, the gastrointestinal system, the urogenital 
system, and the thermoregulatory system, among others. The symptoms 
resulting from malfunction of the autonomic nerves are varied and include 
but are not limited to loss of bladder control, disturbances in heart rate, 
abnormal sweating, nausea, and vomiting. Autonomic nerve dysfunction 
can sometimes be life threatening, especially if cardiovascular or 
respiratory function is disrupted (Novak et al., 2001; Freeman, 2005, 
2007). Motor neuropathies result from altered function of the somatic 
nerves that control voluntary movement of skeletal muscles. 
Consequently, the associated signs and symptoms of motor neuropathy 
are loss of muscle control, painful cramps, muscle atrophy, loss of 
dexterity, and muscle twitching or fasciculation. Sensory neuropathies 
result from dysfunction of the primary afferent nerves that transmit 
information such as vibration, temperature, pain, touch, and limb 
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positioning. The most commonly experienced symptoms associated with 
sensory neuropathy include but are not limited to burning, tingling, loss of 
propioception (position sense), loss of vibration sense, loss of deep 
tendon reflexes and sometimes pain. Peripheral neuropathy can be 
debilitating even in the absence of pain. Patients often report difficulty in 
walking resulting from impaired sense of foot position and skin lacerations 
resulting from kitchen accidents secondary to impaired position sense in 
the hands (Dougherty et al., 2004). There is currently no treatment to 
prevent the loss of sensation that occurs with sensory neuropathies.  
 
Causes of peripheral neuropathy 
Peripheral neuropathy may be either inherited (e.g. Charcot-Marie-
Tooth disease) or acquired. Acquired neuropathy can be caused by 
physical injury to a nerve resulting from traumatic injury, sports-related 
activities, and nerve compression secondary to tumors or by slipped disks 
between vertebrae. Peripheral neuropathies have also been linked to 
systemic diseases or metabolic disorders including diabetes, deficiencies 
of vitamin B1, B6, and B12, kidney disorders resulting in accumulations of 
toxic substances that can affect nerves, and hormonal imbalances 
(Steiner et al., 1988; D'Amour and Butterworth, 1994; Sugimoto et al., 
2000; Kucera et al., 2002; Koike et al., 2003; Koike and Sobue, 2006). 
Some bacterial and viral infections directly cause peripheral nerve 
damage. Viruses like herpes varicella-zoster, Epstein-Barr virus, 
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cytomegalovirus, and human immunodeficiency virus (HIV) can severely 
damage sensory nerves and cause sharp attacks of pain (Fujii et al., 
1982; Rubin and Daube, 1999; Simpson, 2002; de Freitas, 2007; Zhou et 
al., 2007). Leprosy and Lyme disease, which occur after bacterial 
infections, are also characterized by extensive peripheral nerve damage 
(Ooi and Srinivasan, 2004; Mygland et al., 2006). Alternatively, bacterial 
and viral infections can cause indirect nerve damage by eliciting immune 
responses that attack nerves. Such neuropathies are described as 
autoimmune neuropathies (Van Brakel, 2000; Ooi and Srinivasan, 2004). 
Autoimmune neuropathies can be induced by antibodies against the Hu 
antigen on the dorsal root ganglion, GM1 antigens that are concentrated 
at the nodes, myelin or presynaptic calcium channels at the 
neuromuscular junction resulting in interference with release of 
acetylcholine (Ho et al., 1998).  
Of greatest importance to this study is chemotherapy-induced 
peripheral nerve damage resulting from exposure to chemotherapeutic 
agents. These neuropathies can be severe and sometimes interfere with 
the course of therapy (Roelofs et al., 1984; Boogerd et al., 1990; Siegal 
and Haim, 1990; Postma et al., 1999; Peltier and Russell, 2002; 
Verstappen et al., 2003b; Verstappen et al., 2005; Mielke et al., 2006; 
Peltier and Russell, 2006; Scripture et al., 2006; Argyriou et al., 2007). 
The type and the severity of the neuropathy depend on the drug, the dose 
intensity, the cumulative dose, frequency of administration, and pre-
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existing conditions like diabetes or alcoholism (Cata et al., 2006b; 
Windebank and Grisold, 2008). With most drug-induced neuropathies, the 
symptoms can persist for weeks to months after termination of therapy 
and in some instances the neuropathy is irreversible. Discussed below is a 
list of chemotherapeutic agents that are frequently associated with a high 
incidence of peripheral neuropathy in patients. It should be noted that 
although each of the following class of drugs differ in their mechanism of 
action, axonal degeneration is frequently observed in nerve biopsies of 
patients and animal models. 
 
Anti-retroviral drugs 
Of all anti-retroviral agents, the nucleoside reverse transcriptase 
inhibitors (NRTIs) zalcitabine, didanosine, and stavudine are frequently 
associated with a painful sensory neuropathy that is characterized by 
burning, numbness, tingling, and stiffness in the hands and the feet 
(Reliquet et al., 2001; Simpson, 2002). Zalcitabine, didanosine, and 
stavudine are phosphorylated by thymidine kinases and the 
phosphorylated NRTIs compete with the natural substrates for HIV 
reverse transcriptase to inhibit genomic DNA replication. They also 
decrease mitochondrial DNA (mtDNA) replication by inhibiting the enzyme 
γ-DNA polymerase. In virus-infected cells, there is inhibition of viral 
replication while in neuronal cells inhibition of mtDNA results in 
mitochondrial damage (Dalakas, 2001). Indeed, human biopsies of the 
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sciatic nerve from patients treated with zalcitabine revealed enlarged 
mitochondria with extensive vacuolation as well as axonal degeneration 
and myelin degradation (Dalakas, 2001; Dalakas et al., 2001; Reliquet et 
al., 2001).  
 
 
Platinum containing compounds 
The platins (cisplatin, carboplatin and oxaliplatin) are commonly 
prescribed alone or in combination with paclitaxel for the treatment of 
cancers of the breast, ovary, testes, lung, and bladder (Lokich and 
Anderson, 1998; Go and Adjei, 1999) and produce a dose dependent 
sensory neuropathy. The antineoplastic activity of cisplatin and carboplatin 
is related to their ability to form platinum-DNA adducts resulting in 
apoptosis of mitotic cells secondary to inhibition of DNA replication and 
transcription. While the neurotoxic effects of the platinum containing drugs 
correlate with the formation of platinum DNA adducts in dorsal root 
ganglion neurons (Krarup-Hansen et al., 1999; Ta et al., 2006), cisplatin 
has been shown to cause an increased production of reactive oxygen 
species (Jiang et al., 2008). Platinum-induced neuropathy is 
predominantly sensory and is characterized by numbness, tingling, 
paresthesia, reduced vibration sense, loss of proprioception, reduced 
deep tendon reflexes, lack of coordination, and gait disturbance 
(Verstappen et al., 2003a). These sensory symptoms are consistent with 
the observation that high concentrations of cisplatin are observed in the 
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dorsal root ganglion (DRG). Histological examinations of peripheral nerves 
and DRGs revealed degeneration of peripheral sensory nerve axons and 
atrophy of the dorsal root secondary to apoptosis in the DRG (Gregg et 
al., 1992; Krarup-Hansen et al., 1999). 
In addition to crosslinking DNA, oxaliplatin interferes with axonal ion 
conductance and consequently alters neural excitability (Adelsberger et 
al., 2000; Ta et al., 2006). The alteration in neuronal excitability is a likely 
cause of the acute symptoms including paraesthesia, cold 
hypersensitivity, jaw and eye pain, and leg cramps which are observed 
within thirty minutes of infusion of the drug. The early symptoms 
completely disappear within a few days to a couple of weeks but reappear 
with every new course of the drug administered. In addition to acute 
symptoms, patients also develop also develop long lasting symptoms 
including paraesthesias, reduced vibration sense, loss of proprioception, 
reduced deep tendon reflexes, lack of coordination, and gait disturbance 
(Gent and Massey, 2001). 
 
Vinca Alkaloids 
  The vinca alkaloids include the naturally occurring compounds 
vincristine and vinblastine, and the semi-synthetic compounds such as 
vindesine and vinorelbine. Of these drugs, vincristine, prescribed for the 
treatment of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, leukemia, 
and other solid tumors, is most commonly associated with peripheral 
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neuropathy. The vinca alkaloids bind to tubulin and inhibit their 
polymerization into microtubules (Himes et al., 1976). Since microtubules 
are required for the formation of the mitotic spindle during mitosis, loss of 
microtubule function leads to cell cycle arrest and death. In neuronal cells, 
inhibition of microtubule function has been shown to inhibit fast axonal 
transport (Banks et al., 1971a; Dahlstrom and Heiwall, 1975; Samson et 
al., 1979). The most commonly observed symptoms of the neuropathy are 
paraesthesia, pain in fingers and toes, hyperesthesia, and weakness of 
the extensor muscles of the wrist and dorsiflexors of the toes (Peltier and 
Russell, 2002; Dougherty et al., 2007). Vincristine treatment frequently 
causes constipation, paralytic ileus, loss of bladder control, orthostatic 
hypotension and disturbed heart rate associated with autonomic 
neuropathy (Legha, 1986). Sural nerve biopsies obtained from vincristine-
treated patients showed axonal degeneration with segmental 
demyelination (McLeod and Penny, 1969). Results from 
electrophysiological studies suggest that the axonal degeneration occurs 
in a distal to proximal manner (Casey et al., 1973). 
 
Taxanes 
 Taxanes are a class of drugs that include paclitaxel and docetaxel. 
Like the vinca alkaloids, the taxanes also inhibit microtubule function, but 
do so by initially activating microtubule polymerization, and subsequently 
preventing their de-polymerization (Schiff et al., 1979; Manfredi et al., 
	   	   	   	   	   8 
1982; Horwitz et al., 1986) resulting in cell cycle arrest in dividing cells. 
Peripheral neuropathy is more frequently encountered with paclitaxel than 
with docetaxel chemotherapy. Paclitaxel and docetaxel differ in their 
pharmacokinetics and in their pharmacodynamic profiles, which could 
account for dissimilarities in their clinical activity and associated toxicity 
(Rowinsky, 1997; Gligorov and Lotz, 2004). The experiments described in 
this thesis were performed to understand the effects of paclitaxel on 
sensory neurons, since this is the prototype drug of the taxane class. 
 
Toxicities associated with paclitaxel treatment 
 Paclitaxel was originally derived from the bark of the western yew 
tree Taxus brevifolia. It is effective against carcinomas of the ovary, 
breast, lung, head, and neck and is often used as the first line of treatment 
in patients diagnosed with these kinds of cancer. In Phase I studies, 
administration of paclitaxel was complicated by the appearance of life-
threatening type I anaphylactic reactions like urticaria, dyspnea with 
bronchospasm, and hypotension. The hypersensitivity reaction was 
attributed to the polyoxyethylated castor oil (CrEL) vehicle, which is 
required to maintain the lipophilic drug in solution during intravenous 
infusion (Wiernik et al., 1987b). Premedication with corticosteroids like 
dexamethasone and H1 and H2 antagonists, however, decreases the 
incidence of hypersensitivity reactions (Wiernik et al., 1987a; Peereboom 
et al., 1993).  
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 Paclitaxel also causes neutropenia and leucopenia. These toxicities 
can be reversed by decreasing the infusion duration from 24 hrs to 3 hrs 
and co-administering granulocyte colony-stimulating factor (Sarosy et al., 
1992b; Reichman et al., 1993b; Reichman et al., 1993a; Seidman et al., 
1993b; Seidman et al., 1993a). However, decreasing the infusion time to 3 
hours increases the frequency of peripheral neuropathy, the neurologic 
side effect of paclitaxel (Ohtsu et al., 1995; Mielke et al., 2005). 
 
Peripheral neuropathy  
 
Clinical observations 
 Peripheral neuropathy is a dose-limiting toxicity associated with 
paclitaxel and is encountered at doses greater than 200 mg/m2 (or 6 
mg/kg in an individual 72 inches tall and weighing 100 lbs) (Wiernik et al., 
1987b; Cliffer et al., 1998). About 55% of patients receiving a dose of 200 
mg/m2 of paclitaxel per infusion developed neuropathy compared with only 
30% of patients receiving 175 mg/m2 (Lipton et al., 1989). Symptoms such 
as burning, tingling, and numbness usually appear within 24 to 72 hours, 
and resolve within a week after infusion. (Lipton et al., 1989; Iniguez et al., 
1998). The symptoms recur and increase in severity with successive 
courses of infusion and eventually progress to loss of propioception, 
decreased thermal and vibratory threshold, and loss of deep tendon 
reflexes (Wiernik et al., 1987b; Lipton et al., 1989; Sarosy et al., 1992a; 
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Forsyth et al., 1997; Iniguez et al., 1998; Loprinzi et al., 2007). For many 
patients, the symptoms are most pronounced in the tips of the fingers and 
the toes; most experience difficulty in performing routine tasks such as 
writing or buttoning a shirt (Dougherty et al., 2004). Motor neuropathy is 
evident only at doses of 500 mg/m2 or higher (Iniguez et al., 1998). 
Paclitaxel-induced peripheral neuropathy is also dependent on the 
frequency of administration and patients receiving weekly injections of 110 
mg/m2 as opposed to 175 mg/m2 every three weeks developed painful 
symptoms in the hands and the feet. Briasoulis et al. showed that using 
the weekly schedule of 110 mg/m2, the maximum cumulative dose that is 
tolerated by patients is 1500 mg/m2 and the symptoms persist for 1-6 
months after completion of therapy (Briasoulis et al., 2002).  
 Neurophysiologic studies conducted in a patient who received 34 
paclitaxel courses of 275 mg/m2 showed a decrease in the amplitude of 
sural and tibial nerve action potentials (Sahenk et al., 1994). Lipton et al. 
also observed a decrease in amplitude and conduction velocity of the 
sural nerve (Lipton et al., 1989).  
  Myalgia, or muscle pain, has also been observed in patients 
receiving greater than 250 mg/m2 of paclitaxel every three weeks. 
Symptoms are observed during infusion, immediately after infusion, or 2 - 
3 days after treatment but usually resolve within a week. Myopathies, 
neuromuscular diseases from myofiber dysfunction, are very rarely noted 
and have only been seen in patients receiving high doses of paclitaxel 
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(300 - 350 mg/m2), especially when granulocyte colony stimulating factor 
was co-administered (Loprinzi et al., 2007). In addition, deficits in cognitive 
function has not been observed after treatment with the microtubule 
stabilizing drug, as is commonly observed with cisplatin-induced 
neurotoxicity. Furthermore, it is interesting that while autonomic 
dysfunction is frequently observed following treatment with the vinca 
alkaloids, the evidence that paclitaxel affects the autonomic nervous 
system is still inconclusive (Argyriou et al., 2005).  
 Although the mechanisms mediating the neuropathy are not known, 
the decrease in action potential amplitude or conduction velocity suggest 
that paclitaxel causes axonal damage. Indeed, sural nerve biopsy of a 
patient receiving paclitaxel showed a significant reduction in the 
myelinated and unmyelinated fiber density and prominent axonal atrophy 
(Sahenk et al., 1994). The mechanisms mediating this degeneration are 
not known.  
 
Studies in animals 
To study the mechanisms mediating paclitaxel-induced peripheral 
neuropathy, several investigators have injected paclitaxel systemically in 
animals and examined neurophysiologic function, sensory behaviors, and 
morphological changes in sensory nerves.  
Investigators have observed both hypernociception and 
hyponociception in animals that were chronically treated with paclitaxel, 
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and the response observed seems dose-dependent. Animals receiving a 
cumulative dose of up to 10 mg/kg paclitaxel demonstrated a 
hypernociceptive response to mechanical stimuli (Authier et al., 2000; 
Dina et al., 2001; Polomano et al., 2001; Matsumoto et al., 2006; Peters 
et al., 2007; Nishida et al., 2008) but in one study using 25 mg/kg 
paclitaxel, a decreased response to noxious mechanical stimulation was 
observed (Cavaletti et al., 1997). The responses to thermal stimuli also 
varied depending on the dose of paclitaxel administered and the 
frequency of administration. When rats were given a cumulative dose of 
cumulative dose of 25 mg/kg (approximately 175 mg/m2) or higher, they 
showed a decreased sensitivity (antinociception) to thermal stimuli (Apfel 
et al., 1991; Campana et al., 1998; Authier et al., 2000), while animals 
receiving a cumulative dose of 4 to 12 mg/kg had an increased sensitivity 
(hypernociception) to thermal stimuli (Dina et al., 2001; Polomano et al., 
2001; Matsumoto et al., 2006).  
Light and electron microscopy was used to examine degenerative 
changes in the sciatic nerve of paclitaxel-treated animals (Cavaletti et al., 
1995; Authier et al., 2000; Persohn et al., 2005). In electron micrographs 
of sciatic nerves from animals given cumulative doses ranging from 16 to 
80 mg/kg paclitaxel, aggregated microtubules were observed in sciatic 
nerves, and in some cases they were seen surrounding mitochondria 
(Cavaletti et al., 1995; Cavaletti et al., 1997; Authier et al., 2000; Persohn 
et al., 2005). In another study, animals receiving multiple injections of 2 
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mg/kg paclitaxel showed a decrease in the density of nerve fibers in the 
epidermis (Melli et al., 2006; Siau et al., 2006), and this decreased 
density has been observed in other painful sensory neuropathies (Holland 
et al., 1997; Polydefkis et al., 2002; Pittenger et al., 2004; Lauria et al., 
2005). Other investigators observed enlarged or swollen mitochondria in 
electron micrographs of sciatic or saphenous nerves (Cavaletti et al., 
1997; Flatters and Bennett, 2006). Overall, axonal degeneration in sciatic 
nerves of rats is generally associated with cumulative doses of 16 mg/kg 
or greater; axonal damage was not observed at cumulative doses of 8 
mg/kg (Cavaletti et al., 1997; Flatters and Bennett, 2006). Decreased 
sensory nerve conduction velocity in rats treated with paclitaxel often 
correlated with axonal degeneration of the sciatic nerves (Apfel et al., 
1991; Cavaletti et al., 1995; Cavaletti et al., 1997; Cliffer et al., 1998; 
Authier et al., 2000).  
 
Studies on isolated sensory neurons 
Few investigators have examined the effects of paclitaxel on the 
length of neurites in isolated sensory neurons. In some studies paclitaxel 
(6 to 94 nM for 48 hours) prevented outgrowth of neurites in rat DRG 
explants (Konings et al., 1994). In another study, paclitaxel (7 to 350 nM 
for 24 hours) also inhibited neurite outgrowth in isolated chick DRG 
neurons (Letourneau and Ressler, 1984). In contrast, other investigators 
demonstrated that exposure to 28 nM paclitaxel for 24 hours causes the 
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degeneration of already established neurites in embryonic rat DRG 
neurons (Melli et al., 2006; Yang et al., 2009). 
 
Potential effects of paclitaxel on sensory neurons 
Paclitaxel binds to the β subunit of tubulin and promotes the 
assembly of microtubules that are resistant to depolymerization by agents 
that promote their disassembly, namely cold temperature (4ºC) and CaCl2 
(Schiff et al., 1979; Kumar, 1981; Schiff and Horwitz, 1981; Manfredi et 
al., 1982; Horwitz et al., 1986). Thus paclitaxel treatment results in the 
accumulation of abnormal microtubules in the cells (Kumar, 1981; 
Manfredi et al., 1982). In dividing cells, this stabilization of microtubules 
results in cell cycle arrest in its G1 or M phase and apoptosis (Liebmann 
et al., 1993). Microtubule stabilization by paclitaxel has been observed in 
mouse fibroblast cells, synaptosomes prepared from rat forebrains, DRG 
neurons, and a number of cell lines (Schiff and Horwitz, 1980; 
Masurovsky et al., 1981; Burgoyne and Cumming, 1983).  
The role of microtubule stabilization in the etiology of peripheral 
neuropathy is still debated. In sural nerve biopsies from patients with 
paclitaxel-induced neuropathy, no abnormal aggregates of microtubules 
in the axons and Schwann cells were observed (Wiernik et al., 1987b; 
Lipton et al., 1989). Similarly, morphological examination of the 
saphenous nerve from paclitaxel-injected animals (cumulative dose, 8 
mg/kg) showed no abnormalities in microtubules despite the observation 
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of hypernociception in these animals (Flatters and Bennett, 2006). 
Microtubule accumulation was observed in rat sciatic nerve only when the 
cumulative dose of paclitaxel in animals exceeded 16 mg/kg (Cavaletti et 
al., 1997). These results support the notion that microtubule stabilization 
is not the mechanism that accounts for peripheral neuropathy.  
Apart from stabilizing microtubules, paclitaxel has been shown to 
affect mitochondria. In neuroblastoma cells, paclitaxel (1 - 100 µM) 
causes mitochondrial swelling, induces opening of the mitochondrial 
permeability transition pore (mPTP) and cytochrome release (Andre et al., 
2000; Andre et al., 2002). The mitochondrial permeability transition (MPT) 
refers to the depolarization of mitochondria that occurs as a result of 
oxidative stress or calcium overload in the cell. A major consequence of 
the MPT is uncoupling of oxidative phosphorylation resulting in decreased 
production of ATP and further damage to the cell (Halestrap et al., 2002). 
In the saphenous nerve of rats, chronic administration of paclitaxel 
causes mitochondrial swelling. Mitochondrial damage can cause increase 
in intracellular concentration of free radicals. Indeed production of 
reactive oxygen species has been observed in neuroblastoma cells and 
other non-neuronal cell types following treatment with paclitaxel (Andre et 
al., 2002; Wang et al., 2004; Fawcett et al., 2005; Ramanathan et al., 
2005; Alexandre et al., 2006; Alexandre et al., 2007; Kim et al., 2008). 
While a correlation between production of reactive oxygen species and 
opening of the mPTP has been demonstrated in neuroblastoma cells after 
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exposure to paclitaxel (Andre et al., 2000), there is no evidence that the 
microtubule-stabilizing drug alters mitochondrial function or increases free 
radicals in sensory neurons and both of these events remain to be 
explored. 
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Function of microtubules in neuronal cells 
Microtubules are formed by assembly of α/β tubulin heterodimers 
at a fast growing end, which is designated as the “plus end”, while tubulin 
subunits are continually lost from the opposite slow growing or the “minus 
end”. This continuous lengthening and shortening of microtubules defines 
the direction of movement and facilitates the directional transport of 
proteins along axons from the cell body. Accordingly, inhibition of 
microtubule function by drugs like colchicine, vincristine, vinblastine, and 
paclitaxel can potentially interfere with axonal transport. Indeed, Banks et 
al., observed an inhibition of transport of noradrenaline-containing 
vesicles by colchicine and vinblastine in an in vitro preparation of cat 
hypogastric nerve/inferior mesenteric ganglion; this inhibition was 
accompanied by a decrease in the number of axonal microtubules (Banks 
et al., 1971b; Banks et al., 1971a). A similar inhibition of acetylcholine 
transport in cholinergic motor axons was observed after disruption of 
microtubules by colchicine or vinblastine (Heiwall et al., 1976; Heiwall et 
al., 1978). While paclitaxel’s mechanism of microtubule inhibition is 
different from that of colchicine and vinblastine, paclitaxel nonetheless 
inhibits the transport of proteins in DRG neurons and in the sciatic nerve 
in vitro (Nakata and Yorifuji, 1999; Theiss and Meller, 2000; Shemesh 
and Spira, 2010).  
In neurons, microtubules are especially important for the 
anterograde transport of mitochondria from the soma to regions of high 
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ATP consumption including the nodes of Ranvier, the tips of growth 
cones, and synaptic terminals (Morris and Hollenbeck, 1995; Gallo and 
Letourneau, 1999; Ligon and Steward, 2000). Mitochondrial localization at 
synapses is crucial for buffering the large increases in intracellular 
calcium that occur during depolarization. Mitochondria also provide ATP 
as an energy source for exocytosis and for vesicle recycling. Decreased 
density of mitochondria at synapses is thought to occur early in the 
progression of neurodegenerative diseases. Thus it seems possible that 
disruption of transport of mitochondria by paclitaxel could be a 
mechanism for drug-induced peripheral neuropathy. Indeed, disruption of 
microtubule function causes accumulation of mitochondria in the cell body 
suggesting that anterograde transport of mitochondria is inhibited (Morris 
and Hollenbeck, 1995; Wang et al., 2003a). Treatment of hippocampal 
neurons with the microtubule targeting drug vinblastine causes 
mitochondria to accumulate away from the plasma membrane. 
Consequently NMDA-evoked larger [Ca2+]i increases in vinblastine 
treating neurons suggesting that localization of mitochondria at the site of 
calcium influx Is important for sequestration for calcium (Wang et al., 
2003a). One inference from these data is that inhibition of microtubules in 
primary afferent sensory neurons by paclitaxel inhibits transport of 
mitochondria to nerve endings and that this results in decreased buffering 
of intracellular calcium at the peripheral endings of sensory neurons. 
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Classification of sensory neurons 
The DRGs contain the cell bodies of the primary afferent sensory 
neurons, and these neurons convey sensory information from the 
periphery to the spinal cord. The neurons are pseudounipolar: they have 
a single axon that bifurcates into a peripheral branch that terminates in 
the skin, muscle, or visceral organs, and a central branch that terminates 
in the spinal cord. The DRGs contain a heterogeneous population of 
neurons that relays a spectrum of sensory information including 
discriminative touch, pressure, nociception (signaling of tissue damage 
usually perceived as pain or itch), propioception (position in space) and 
temperature. As can be seen in Table 1, several criteria exist for the 
classification of sensory neurons.  
Of primary importance to the current work are the Aδ and the C 
fibers that are activated by noxious thermal, mechanical, or chemical 
stimuli. While some of these sensory neurons are activated only by 
specific stimuli (only mechanical or only thermal), others respond to 
multiple stimuli (thermal, mechanical and chemical): these fibers are 
usually the C fibers and are commonly known as polymodal nociceptors 
(Besson, 1999). The C fibers constitute 80% of the axons terminating in 
the skin and together with the Aδ fibers, they are located mostly at the 
junction of the dermis and epidermis in close proximity with dermal blood 
vessels (Lumpkin and Caterina, 2007).  
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Diameter of 
axons 
15 - 20 
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Although it is well accepted that peripheral neuropathy induced by 
paclitaxel results from impaired function of myelinated fibers, the 
involvement of small diameter sensory neurons is ambiguous. Based on 
symptoms reported by patients undergoing chemotherapy with paclitaxel, 
Dougherty et al., postulated that myelinated fiber function is impaired, 
while function of the unmyelinated C fibers is preserved (Dougherty et al., 
2004). Additionally, studies in animals revealed pathology of myelinated 
fibers in electron micrographs (Cliffer et al., 1998), while no changes in 
the conduction velocity of C fibers were observed following systemic 
administration of paclitaxel (Dina et al., 2001). In contrast, a sural nerve 
biopsy from a patient receiving paclitaxel showed degeneration of 
myelinated and unmyelinated fibers (Sahenk et al., 1994). Furthermore, in 
rats treated with paclitaxel (cumulative dose 80 mg/kg) degeneration of 
myelinated and unmyelinated fibers was observed (Authier et al., 2000). 
Because the hypernociception observed following systemic administration 
with paclitaxel suggest involvement of the small diameter peptidergic 
fibers (lightly myelinated Aδ and unmyelinated C fibers), it is possible that 
the function of these fibers is altered after systemic administration of 
paclitaxel.  
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Molecular mechanisms of sensory transduction 
The transduction of sensory stimuli is mediated by molecular 
structures or receptors expressed on the peripheral endings of sensory 
neurons. The cell surface receptors that are activated by sensory stimuli 
include a wide repertoire of ligand gated ion channels, G-protein coupled 
receptors, and receptors with tyrosine kinase activity (Lumpkin and 
Caterina, 2007). One such family of receptors is the ion channels 
belonging to the transient receptor potential family (TRP). Some TRP 
channels like TRPM8 and TRPA1 respond to cold temperatures i.e., they 
are activated by cooling from normal skin temperature (about 32ºC) to 
below 30°C and below 20°C, respectively (McKemy, 2005; Madrid et al., 
2006; Bautista et al., 2007; Caterina, 2007; Dhaka et al., 2007). Another 
family of channels known as the acid sensing ion channels (ASICs) are 
also expressed on nociceptive neurons and activated by low pH (< 6.6) 
(Krishtal, 2003).  
Of major importance in pain perception is the non-selective cation 
channel TRPV1 that is expressed on a subset of Aδ and C fibers. 
Activation of this channel by heat (> 43ºC) or low pH (Caterina et al., 
1997) excites small diameter sensory neurons and evokes nociceptive 
responses. TRPV1 can also be activated by the vanilloid capsaicin, which 
mimics the actions of a physiological stimulus or an endogenous ligand 
produced during tissue injury. Capsaicin is therefore a valuable 
pharmacological tool for the examination of TRPV1 function. Activation of 
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the TRPV1 channel by capsaicin, heat or protons results in an influx of 
calcium and sodium ions into neuron. Sometimes the depolarization 
induced by divalent cations is sufficient to induce opening of voltage 
gated sodium channels (VGSCs). Entry of sodium through VGSCs 
causes the neuron to fire action potentials. Propagation of the action 
potentials through the axon to the central terminals in the spinal cord 
induces opening of the voltage gated calcium channels (VGCC) in the 
nerve terminals in the spinal cord. The resultant influx of calcium ions via 
VGCCs causes release of neurotransmitters like CGRP, substance P, 
and glutamate in the spinal cord.  
While release of neurotransmitters in the spinal cord requires 
propagation of action potentials along primary afferent fibers, release of 
CGRP and SP from the peripheral terminals of the sensory neuron can 
occur in the absence of action potentials, i.e. the depolarization produced 
by influx of calcium and sodium ions in the periphery is sufficient to cause 
neurotransmitter release (Maggi, 1991). Because CGRP and SP can be 
released from central terminals as well as peripheral terminals, they 
perform dual functions as discussed below. Therefore examination of 
release of the neuropeptides from sensory neurons can be used as an 
indicator of sensory neuron function.  
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Dual function of CGRP: as a neurotransmitter and vasodilator 
CGRP is a 37-amino acid peptide produced by alternative splicing 
of the calcitonin gene. It belongs to a family that also includes 
adrenomedullin (AM) and amylin. Two forms of CGRP exist: α-CGRP and 
β-CGRP. The two forms of CGRP differ from each other by 3 amino 
acids, although β-CGRP is expressed from a separate gene that does not 
produce calcitonin. Both forms of CGRP are widely distributed in the 
central and the peripheral nervous system and they display very similar 
biological activities. Of the two CGRP isoforms, α-CGRP is abundant in 
sensory neurons, while β-CGRP is expressed in enteric neurons and in 
the pituitary gland (Brain and Grant, 2004). 
CGRP is synthesized in the cell bodies of sensory neurons and 
transported in large dense core vesicles to the nerve terminals (Kashihara 
et al., 1989). In the dorsal horn of the spinal cord, CGRP-like 
immunoreactivity is detected in the tract of Lissauer, and the presynaptic 
terminals in laminae I, II, and V of the spinal cord. Dorsal rhizotomy 
causes approximately a 95% decrease in CGRP immunostaining in the 
dorsal horn, suggesting that the CGRP is localized to the presynaptic 
terminals of the primary afferent sensory neurons (Gibson et al., 1984). In 
the rat, approximately 46.5% of DRG neurons stain for CGRP. These 
neurons are a subset of the C and Aδ type (McCarthy and Lawson, 
1990). 
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The receptor for CGRP is a G-protein coupled receptor (GPCR) 
consisting of two proteins: the calcitonin receptor-like receptor (CL), which 
is associated with G proteins, and a receptor activity modifying protein 
(RAMP). RAMP is important for membrane localization of the receptor 
and for conferring ligand specificity (McLatchie et al., 1998; Foord and 
Marshall, 1999). Three RAMPS have so far been identified: RAMP1, 
RAMP2, and RAMP3. The association of CL with RAMP1 is the CGRP1 
receptor that is activated by αCGRP (Chakravarty et al., 2000; Brain and 
Grant, 2004), while association of RAMP2 or RAMP3 with CL are 
receptors for adrenomedullin (McLatchie et al., 1998; Chakravarty et al., 
2000). The binding of CGRP to the CGRP1 receptor can be blocked by 
CGRP8-37 (Chiba et al., 1989). CGRP also binds to another receptor 
(CGRP2) and this binding is not antagonsied by CGRP8-37 (Hay, 2007). 
The molecular identity of CGRP2 is not known and will not be discussed 
further. The CGRP1 receptor is widely expressed in the brain, in the 
dorsal horn of the spinal cord, and on cell bodies of sensory neurons (van 
Rossum et al., 1997). Outside the nervous system, CGRP1 is expressed 
in the heart, lung, kidney, spleen, skeletal muscle, on lymphocytes, 
vascular smooth muscle cells, mast cells, and endothelial cells.  
CGRP release can be evoked by stimuli that activate the small 
diameter sensory neurons (e.g. capsaicin, low pH, bradykinin and heat). 
When released from the central terminals in the dorsal horn, CGRP 
produces a modest depolarization in second order neurons (Ryu et al., 
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1988a). CGRP also has an autocrine function: in cultured DRG neurons, 
CGRP elevates intracellular calcium and induces inward currents through 
voltage-gated TTX-resistant sodium channels (Natura et al., 2005). 
Additionally, it enhances excitatory synaptic transmission by increasing 
calcium currents in DRG neurons (Ryu et al., 1988b; Ryu et al., 1988c). 
Furthermore, CGRP increases the spontaneous release of glutamate in 
spinal cord slices (Kangrga et al., 1990; Kangrga and Randic, 1990). The 
effects of CGRP are thought to result from the stimulation of adenylyl 
cyclase and production of cAMP (Hirata et al., 1988; Crossman et al., 
1990; Van Valen et al., 1990; Takhshid et al., 2006).  
CGRP is also released from the peripheral terminals of small 
diameter sensory neurons during inflammation or by application of 
capsaicin (Kilo et al., 1997; Kress et al., 1999; Petho et al., 2004). Local 
depolarization induced by capsaicin or by low pH can trigger the release 
of CGRP via the influx of calcium (Maggi, 1991). Notably, release by both 
agents is insensitive to inhibitors of voltage-sensitive Ca2+ channels 
(VSCC), lidocaine, and to high concentrations of TTX, suggesting that the 
influx of calcium via TRPV1 is sufficient to cause local neurotransmitter 
release.  
Axon reflexes also might contribute to the release of CGRP in the 
periphery. The peripheral endings of the Aδ and C fibers are highly 
branched. Action potentials resulting from activation of peripheral endings 
propagate centrally, but can sometimes propagate antidromically 
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(backwards) from the branch point to other peripheral branches, resulting 
in release of neuropeptides (Figure 1). 





Figure 1. Proposed mechanism of axon reflex mediated vasodilatation. 
When stimuli such as low pH, bradykinin, capsaicin and heat activate a 
branch of the peripheral ending of a nociceptive neuron, the generated 
impulse propagates centrally to the local branch point (indicated by the 
black arrow). From here the impulse is reflected down the other branches 
to cause release CGRP on to effector organs e.g. the blood vessels. 
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 A third potential mechanism mediating release of CGRP in the 
periphery involves antidromic stimulation of the Aδ and C fibers by action 
potentials that are triggered in the spinal cord (Lin et al., 1999; Weng and 
Dougherty, 2005). These action potentials are also known as dorsal root 
reflexes (DRRs) and they are initiated by excessive primary afferent 
depolarization (PAD) of the central terminals in the spinal cord. The 
mechanism of PAD involves the role of GABAergic interneurons. When 
action potentials initiated in the periphery trigger GABA release from 
interneurons, GABAA receptors on presynaptic terminals of sensory 
neurons are activated resulting in Cl- efflux and depolarization. This 
depolarization then propagates to the periphery as a DRR (Willis, 1999).   
Vasodilatation is an important biological effect of CGRP release 
from peripheral terminals of sensory neurons. When the peripheral 
endings of sensory neurons are activated by bioactive substances at the 
site of injury, the resulting release of CGRP and SP not only directly 
induce vasodilatation, but they also act on mast cells and other immune 
cells to release proinflammatory substances that contribute to 
inflammation i.e. redness and warmth (secondary to vasodilatation), 
swelling, and hypersensitivity (Richardson and Vasko, 2002). 
Vasodilatation results in enhanced delivery of different populations of 
cells of the immune system (e.g. monocytes, macrophages, T 
lymphocytes, and mast cells) to facilitate tissue repair and wound healing 
(Onuoha and Alpar, 2001; Irie et al., 2002; Li et al., 2007). CGRP-induced 
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vasodilatation has been demonstrated in many organs including the skin, 
lung, joints, heart, and kidney (Brain et al., 1985; Brain et al., 1986; 
Martling et al., 1988; Hughes and Brain, 1991; Brain et al., 1992; Escott 
and Brain, 1993; Chin et al., 1994; Escott et al., 1995). In these organs, 
CGRP expressing sensory neurons (Aδ and C fibers) are localized near 
blood vessels. Activation of the CGRP1 receptor, expressed on 
endothelial cells as well as vascular smooth muscle cells, (Hirata et al., 
1988; Crossman et al., 1990) causes smooth muscle relaxation and 
subsequent vasodilatation.  
CGRP produces vascular smooth muscle relaxation directly by 
stimulating receptors on vascular smooth muscle cells and indirectly by 
activating endothelial cells. In cerebral arteries from the cat and porcine 
coronary arteries CGRP causes relaxation in the absence of the 
endothelium, suggesting that CGRP acts directly on smooth muscle cells. 
Relaxation of these vessels correlates closely with increased intracellular 
cAMP in the cerebral artery of the cat and coronary arteries of the rat and 
pig (Edvinsson et al., 1985; Yoshimoto et al., 1998). In contrast, 
relaxation of the rat aorta requires an intact endothelium: the relaxation 
correlates with an increase in cAMP and cGMP in coronary arteries from 
rats and pigs, and is antagonized by nitric oxide synthase inhibitors, 
suggesting the involvement of nitric oxide from endothelial cells 
(Yoshimoto et al., 1998; Wisskirchen et al., 1999). Direct smooth muscle 
relaxation secondary to an increase in cAMP in these cells is thought to 
	   	   	   	   	   31 
result from activation of PKA, and subsequent phosphorylation of K+ 
channels. Furthermore, Nelson et al. showed that arterial dilations by 
CGRP can be inhibited by glibenclamide, a KATP channel blocker (Nelson 
et al., 1990).  
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Methods to study peripheral neuropathy in animal models 
As mentioned above, the end points currently used for the 
examination of paclitaxel-induced changes in peripheral nerve function in 
animals include nociceptive behavior, nerve biopsies, and 
electrodiagnostic testing. The major nociceptive behaviors that have been 
examined include measuring paw withdrawal in response to thermal or 
mechanical stimuli. A shorter withdrawal latency is interpreted as a 
hypernociceptive response to a stimulus and a longer latency is 
interpreted as anti-nociception. Electrodiagnostic studies are also often 
performed to assess nerve fiber integrity in animal models. There are two 
primary types of electrodiagnostic studies: nerve conduction studies and 
electromyography (EMG). Nerve conduction studies are performed to 
determine the shape, amplitude, latency, and velocity of action potentials 
conducted by a nerve and to help determine if the neuropathy is the result 
of axonal degeneration or demyelination. With axonal degeneration, the 
amplitude of the action potential is lower, while demyelination of nerves 
results in longer latencies and slow conduction velocities. EMG studies 
test spontaneous muscle fiber activity and activity after nerve stimulation. 
However, a limitation of electrodiagnostic studies is that they test the 
function of only the large, myelinated neurons and are not strong 
indicators of potential alterations in function of the small diameter sensory 
neurons (Holland et al., 1997; Griffin et al., 2001). In such cases, skin 
biopsies to determine intraepidermal or dermal fiber density can be 
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examined because the epidermis is richly innervated by small diameter 
fibers, namely the unmyelinated C fibers and the thinly myelinated Aδ 
fibers, both of which are easily distinguishable at the light microscope level 
after immunostaining for axonal markers (Holland et al., 1997; Periquet et 
al., 1999; Pittenger et al., 2004; Lauria et al., 2005; Sommer and Lauria, 
2007; Tavee and Zhou, 2009). However, as described below, sensory 
neuron mediated cutaneous vasodilatation was used as an endpoint in the 
studies conducted in this thesis because it is a non-invasive method to 
assess small diameter sensory neuron function in vivo. 
 
Measurement of vasodilatation in the study of paclitaxel-induced 
peripheral neuropathy 
 Peripheral neuropathy induced by paclitaxel encompasses 
symptoms that indicate dysfunction of all classes of sensory neurons. The 
loss of propioception, vibration sense, and deep tendon reflexes indicate 
that the function of the large fibers is compromised. The elevated thermal 
nociceptive threshold, burning, tingling, and numbness are symptoms 
which are characteristic of small fiber neuropathies (Tavee and Zhou, 
2009). Because nerve conduction studies are not suitable for examining 
function of small diameter sensory neurons in vivo, the studies conducted 
for this thesis examined CGRP release indirectly - by measuring 
cutaneous vasodilatation. Cutaneous vasodilatation is mediated by small 
diameter sensory neurons that release peptides and whose peripheral 
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terminals are localized in the upper dermis close to blood vessels. For 
these studies sensory neurons were activated by capsaicin, the ligand for 
the TRPV1 ion channel (Caterina et al., 1997) since these channels are 
found on 60% of peptidergic neurons that innervate the skin (Hwang et al., 
2005). Intradermal injection of capsaicin or electrical stimulation of the 
sciatic nerve has been used by some investigators to evoke vasodilatation 
in the skin (Koltzenburg et al., 1990; LeVasseur et al., 1990; Escott and 
Brain, 1993; Lin et al., 1999). There is precedent in the literature that 
diseases which result in peripheral neuropathy are associated with a 
decrease in vasodilatation after sensory nerve stimulation. These include 
diabetic neuropathy (Forst et al., 1997; Caselli et al., 2003; Kramer et al., 
2004; Caselli et al., 2006), and port herpetic neuralgia in elderly patients 
(LeVasseur et al., 1990). Thus it seems possible that this phenomenon 
could occur after paclitaxel treatment. Consequently, examination of 
cutaneous vasodilatation is a relevant method to examine changes 
sensory neuron function secondary to treatment with paclitaxel. 
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SPECIFIC AIMS OF THE THESIS 
The studies outlined in this thesis examine the effects of the cancer 
chemotherapeutic drug paclitaxel on small diameter sensory neurons and 
determine the mechanisms responsible for functional changes. Therefore, 
the aims of this thesis are:  
1. To determine the effects of paclitaxel on release of CGRP from 
small diameter sensory neurons. 
2. To determine if paclitaxel alters the length of neurites in isolated 
sensory neurons. 
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MATERIALS AND METHODS 
 
Materials 
Tissue culture plates were purchased from Becton-Dickinson (San 
Jose, CA). F-12 media, horse serum, antibiotics, and Normocin-OTM, 
annexin V-FITC, NuPAGE® Novex Bis-Tris Gels, NuPAGE® MES 
western blot running buffer, NuPAGE® sample reducing buffer, NuPAGE® 
MES transfer buffer, SeeBlue® Plus2 prestained standard, PVDF 
membranes and filter paper sandwiches were purchased from Invitrogen 
(Carlsbad, CA). TaqMan® Universal PCR master mix, MicroAmp® Fast 96 
well plates for real time PCR, MicroAmp® optical adhesive film, probe and 
primer sets for relative quantification of mRNA for TRPV1, Nav1.9, and the 
endogenous control GAPDH were purchased from Applied Biosystems 
(Foster City, CA). Reagents for protein quantification (bovine IgG protein 
and Bradford reagent), and iScriptTM cDNA synthesis kit, supplies for 
biolistic transfection of neurons, including tubing, gold, 
polyvinylpyrrolidone (PVP), tubing Prep Station, Helios Gene Gun, Gene 
Gun Barrels and Cartridge holders were purchased from Bio-Rad 
Laboratories (Hercules, CA). High grade dehydrated ethanol for biolistic 
transfection of sensory neurons was ordered from Spectrum Chemical 
MGF. CORP. (Gardena, CA). CGRP for radioimmunoassay and for 
vasodilatation experiments was purchased from Tocris Bioscience 
(Ellisville, MO). Rat (Tyr27)-αCGRP27-37 for radioimmunoassay was 
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purchased from Bachem (Torrance, CA). Radiolabeled NaI (125NaI) for 
iodination of CGRP27-37 and Western Lightning® Plus-ECL Enhanced 
Chemiluminescence substrate were purchased from Perkin-Elmer 
(Shelton, CT). Anti-goat TRPV1 antibody and blocking peptide were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). HRP 
conjugated donkey anti-goat IgG was purchased from Jackson 
ImmunoResearch Laboratories (West Grove, PA). Donkey serum was 
purchased from Millipore (Billerica, MA). Radiographic film was purchased 
from RPS imaging (Michigan City, IN). PrepEase® RNA Spin Kit for 
extraction of RNA was purchased from USB corporation (Cleveland, OH). 
Trevigen CometSlides for COMET assay were purchased from Trevigen 
(Gaithersburg, MD). Unless otherwise specified, all chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO). 
 
Experimental animals 
The Animal Care and Use Committee at Indiana University School of 
Medicine, Indianapolis, IN approved all procedures used in these studies. 
Adult male Sprague Dawley rats were purchased from Harlan 
(Indianapolis, IN). Whenever required, rats were housed in groups in a 
light controlled room (light from 6:00 to 19:00) at a constant temperature of 
22oC. All animals were allowed to acclimate for at least 3 days after 
delivery and before administering injections. Food and water were 
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available ad libitum. Animals for DRG harvests were sacrificed on the day 
they were delivered. 
 
Paclitaxel administration for in situ experiments 
To study the effects of paclitaxel on sensory neuron function in vivo, 
the injection schedule established by Polomano et al., was used 
(Polomano et al., 2001). This schedule was chosen because it produces a 
change in sensory behavior without any overt signs of toxicity. Paclitaxel 
was initially reconstituted in dimethyl sulfoxide (DMSO) to a concentration 
of 10 mg/ml, and aliquots were stored at -20°C. The drug was further 
diluted to 1mg/ml in phosphate buffered saline so that the final 
concentration of DMSO was 10%. Male Sprague Dawley rats (175 to 180 
grams) were weighed prior to administering intraperitoneal injections of 1 
mg/kg, 2 mg/kg, or 4 mg/kg paclitaxel every other day for a total of 4 
doses. Vehicle-injected animals received intraperitoneal injections of 10% 
DMSO in phosphate buffered saline (PBS). Rats belonging to different 
treatment groups were housed in different cages. Experiments were 
performed one week after the last injection. As seen in Figure 2, 
paclitaxel-injected rats gained weight normally. On the day of the 
experiment, animals weighed 250 to 260 grams.  




Figure 2. Paclitaxel-injected animals gain weight normally. Each data point 
is the mean ± SEM gram weight of 6 to 10 rats, over the times indicated. 
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Blood flow measurement by laser Doppler flowmetry 
Cutaneous blood flow was measured by a BLF21D laser Doppler 
flowmeter from Transonic systems Inc. (Ithaca, NY) using a type N 11 G 
needle-style probe placed on the skin. With this method, vasodilatation in 
the dermis can be recorded non-invasively. A low intensity beam of 
monochromatic light travels from a laser diode in the flowmeter via a fiber 
optic cable through the laser probe head and illuminates the tissue being 
examined. The laser beam is then reflected back by the tissue 
components as well as by moving objects such as blood cells. The fiber 
optic cable guides the reflected light back to the flowmeter where it is 
received by a photo detector. The volume of tissue sampled is 
approximately 0.6 mm3 and blood flow is recorded in terms of tissue 
perfusion units. Because the laser penetrates to a depth of approximately 
600 µM, laser Doppler flow probe presumably detects changes in blood 
flow from the microvasculature in the dermis. For experimental set-up, see 
Figure 3. 
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All measurements were made on the hairy skin of the rat hind paw. 
This region of the hind paw is innervated by the L4 and L5 ganglia 
(Takahashi and Nakajima, 1996). Rats were placed on a heated platform 
to maintain body temperature at 37ºC. The laser probe was allowed to 
warm up for at least 10 minutes, and the heated platform was allowed to 
reach a stable temperature of 37ºC prior to beginning any blood flow 
measurements. In all experiments, vasodilatation was measured in rats 
weighing 250 - 260 grams. They were allowed to acclimate in their cages 
in the laboratory for at least 1 hour before being anesthetized with 100 
mg/kg i.p. sodium thiopenthal. The hair of the dorsal surface of the paw 
was shaved and the rat was placed on the heated platform for 30 minutes 
before initiating blood flow measurements. The 30-minute period of 
acclimation was chosen to stabilize body temperature of the rat at 37ºC. 
since fluctuations in body temperature can alter basal blood flow. After the 
initial acclimation, basal blood flow was recorded for approximately 10 
minutes until it stabilized. After stabilization of baseline blood flow, a 27G 
needle was inserted into the skin at an angle of 15 degrees to ensure 
intradermal placement of the needle. Placement of a 27G needle 
intradermally did not cause significant changes in baseline blood flow 
(Figure 4). An additional baseline blood flow in the presence of the needle 
was recorded for 15 minutes.  
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Characterization of cutaneous blood flow after intradermal injection of 
capsaicin 
Experiments were performed initially to develop a protocol for the 
measurement of capsaicin-induced vasodilatation. After baseline blood 
flow (in the presence of the needle) stabilized, 10 µM capsaicin in 10 µl 
was injected intradermally. Figure 4 shows that blood flow increased from 
18 ± 2 to 24 ± 1 TPU/min. This response was modest in comparison to 
observed effects of capsaicin in published reports (Hughes and Brain, 
1991; Lin et al., 1999). This was a major concern for the planned studies 
because the weak response could prevent observations of changes in 
drug treated animals. 




Figure 4. Intradermal injection of capsaicin increases blood flow in the skin 
of the rat hind paw. Each column is the mean ± SEM. The open columns 
and the light shaded columns represent basal blood flow before and after 
intradermal placement of the injection needle respectively. The dark 
shaded columns represent blood flow after injection of vehicle (0.01% 
MPL in PBS) (A) or 10 µM capsaicin (B).  
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 There are two possible reasons for the weak response to intradermal 
injection of capsaicin: First, since the flow probe is able to detect changes 
in blood flow only within a 1 mm2 area, the probe might be too far from the 
injection site. Second, the volume of injection (10 µl) might interfere with 
the detection of a response by the laser probe. To resolve these issues 
injections were made 1 mm away from the site of the probe and the 
injection volume was decreased to 1 µl in future experiments. 
 
Characterization of cutaneous blood flow after electrical stimulation of the 
sciatic nerve 
For examination of changes in blood flow in response to sciatic nerve 
stimulation, the animal was removed from the heated platform after 
stabilization of baseline. The sciatic nerve was exposed in the groove 
between the dorsal side of the ischeum and sacral bone. To prevent 
injury-induced action potentials, 1% lidocaine was applied to the trunk of 
the sciatic nerve with a cotton-tipped applicator. The nerve was cut 
proximal to the lidocaine application site and was placed into a nerve cuff 
fitted with a silver-stimulating electrode (Figure 5). A layer of petroleum 
jelly was applied over the stimulating electrode, the skin was sutured, and 
the animal was returned to the heated platform. Baseline blood flow 
following axotomy was recorded for 30 minutes to allow sufficient time for 
the lidocaine block to be extinguished., A stimulus amplitude of 5mA at 10 
Hz for 30 seconds was used to stimulate the sciatic nerve (Koltzenburg et 
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al., 1990). The increase in blood flow following the stimulation was 
recorded for an additional 30 minutes. 
To determine if the vasodilatation induced by capsaicin or sciatic nerve 
stimulation is mediated by CGRP, 20 µM of the CGRP receptor antagonist 
CGRP8-37 was injected intradermally 5 minutes before drug injection or 
before electrical stimulation (Hughes and Brain, 1991; Escott and Brain, 
1993). To assure that the CGRP8-37 and capsaicin were injected at the 
same site, two 30 G needles were glued together. One needle was 
connected to a syringe containing capsaicin and the other needle to a 
syringe filled with the CGRP receptor antagonist.  
 
Examination of blood flow in paclitaxel injected animals 
 In experiments to determine if paclitaxel altered sensory neuron 
function, vasodilatation in response to intradermal capsaicin or electrical 
stimulation was examined in paclitaxel-injected animals using the 
procedures detailed above. To determine if vascular smooth muscle 
function in paclitaxel-treated animals was intact, methacholine (100 µM) or 
α-CGRP (30 µM) was injected intradermally.  
The data for all blood flow experiments are presented as the mean 
response ± SEM recorded per 3-minutes in tissue perfusion units (TPU) 
for each animal. To determine if there were statistically significant 
differences blood flow between treatment groups, I compared the mean ± 
SEM of the evoked response/15 minutes between treatment groups using 
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one-way analysis of variance (ANOVA) and Bonferroni’s post hoc test. 
Evoked response was calculated by subtracting the baseline response for 
15 minutes before the injection of capsaicin or electrical stimulation from 
the response for 15 minutes after stimulation.  
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Figure 5. Schematic representation of the sciatic nerve stimulation 
experiment. The stimulator was placed on the trunk of the sciatic nerve 
(before it branched into the sural, peroneal and tibial branches). The site 
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Neuropeptide release from spinal cord slices 
For experiments measuring release of CGRP from spinal cord slices, 
male Sprague Dawley rats were injected with paclitaxel or vehicle as 
indicated above, then sacrificed, and spinal cord slices were prepared as 
previously described (Chen et al., 1996). Rats were anaesthetized by 
carbon dioxide asphyxiation and then decapitated. The spinal column was 
dissected out, and the spinal cord was extruded through the rostral end of 
the column using PBS. The lumbar region was identified as a distinct 
swelling or enlargement at the caudal end, and 1 cm of this lumbar 
enlargement was dissected. The dorsal horn of the spinal cord was 
dissected and chopped, first cross-sectionally and then parasagitally into 
0.3 x 0.3 mm sections. The tissue was weighed, placed into a cylindrical 
perfusion chamber with an internal volume of 0.5 ml, and perfused with 
buffer consisting of HEPES 25 mM, NaCl 135 mM, KCl 3.5 mM, MgSO4 1 
mM, CaCl2 2.5 mM, dextrose 3.3 mM, bovine serum albumin 1%, and 
ascorbic acid 200 µM. The buffers also contained the peptidase inhibitors 
phe-ala (100 µM), bacitracin (20 µM), phenyl methane sulphonyl fluoride 
(PMSF-100 µM), and phosphoramidon (1 µM) to minimize breakdown of 
CGRP (Chen et al., 1996). The inhibitors were prepared from stock 
solutions that were stored at 1000 times the final concentration at -20ºC. A 
stock concentration of 10 mM capsaicin in 1-Methyl-2-pyrrolidone (MPL) 
was prepared and was further diluted to 500 nM with HEPES buffer. The 
buffers were continuously aerated with 95% 02 + 5% CO2 and pH 7.4-7.5, 
	   	   	   	   	   50 
and maintained at 37o C throughout the experiment. The tissue was 
perfused at a flow rate of 0.5 ml/min. The perfusate from the first 20 
minutes was discarded, after which perfusate fractions were collected into 
test tubes containing 75 µl of 1M 2-(N-morpholino) ethanesulfonic acid 
(MES) buffer, pH 6.7-6.9 every 3 minutes. Basal release was established 
by first perfusing the tissue with HEPES buffer for 18 min, after which the 
tissue was exposed to HEPES buffer containing either 500 nM capsaicin 
or 30 mM KCl substituted for equimolar NaCl for 9 minutes to evoke 
release of CGRP. To demonstrate a return to basal release after 
stimulation, the tissue was perfused with HEPES buffer for another 15 
minutes. For a schematic representation of the perfusion apparatus, see 
Figure 6. 
At the end of the experiment, the tissue was removed from the 
chambers and homogenized in 0.01 M HCl, then centrifuged for 20 min at 
3000 x g at 4ºC in a Beckman-Coulter AllegraAM 6R centrifuge (Fullerton, 
CA). The supernatant was diluted with HEPES buffer, and total peptide 
content remaining in the tissue as well as that in the perfusate fractions 
was measured by radioimmunoassay. The total content of iCGRP was 
calculated as the amount of iCGRP remaining in the tissue at the end of 
the experiment added to the amount in each of the 14 perfusate fractions. 
The CGRP release is referred to as immunoreactive CGRP (iCGRP). 
Release data from spinal cord slices are expressed as the mean ± SEM of 
the fractional release of iCGRP (% of total content). For analysis of CGRP 
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release from spinal cord slices, the sum of the iCGRP released in the 3 
fractions before exposure to the stimulus (basal release/9 minutes) was 
subtracted from the sum of the iCGRP released in the 3 fractions during 
exposure to the stimulus (stimulated release/9 minutes) to give the evoked 
release of iCGRP in 9 minutes (evoked release/9 minutes). The evoked 
release was compared using an unpaired t test between control and 
paclitaxel-treated animals. Statistical significance was set at p < 0.05. 




Figure 6. Schematic representation of the CGRP release assay from 
spinal cord slices.  
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Adult rat dorsal root ganglion culture preparation 
Cell culture plates were precoated the day before the DRG harvest 
by exposing them to 1 ml poly-D-lysine (1mg/10 ml; 70,000 - 150,000 MW) 
for 1 hour, rinsing with ddH2O and then exposing them to 1 ml laminin (1 
mg/ml) at 37ºC overnight. The laminin was removed just before plating the 
dissociated cells (see below). Adult rat DRG cell cultures were prepared 
as previously described (Burkey et al., 2004). Adult male Sprague Dawley 
rats weighing 175 to 200 grams were euthanized by CO2 asphyxiation. 
The DRGs were collected from the entire spinal column (from cervical to 
sacral levels), and the afferent fibers were trimmed off. Next, the ganglia 
were incubated in Ham’s F-12 medium containing 0.125% collagenase for 
1 h in 3% CO2 at 37ºC, and then were centrifuged and resuspended in F-
12 medium supplemented with 10% horse serum, 2 mM glutamine, 100 
µg/ml normocin, 50 µg/ml penicillin, 50 µg/ml streptomycin, 50 µM 5-
fluoro-2′-deoxyuridine, 150 µM uridine, and 30 ng/ml NGF. The DRGs 
were then dissociated by triturating with fire polished pasteur pipettes. An 
aliquot (30 µl) of the dissociated cell suspension was diluted 1:2 with 
trypan blue, and the number of live cells (those that exclude trypan blue) 
was counted using a haemocytometer. The suspension was diluted to 
30,000 live cells/ml, and 1 ml of this suspension was plated in each well of 
a 12-well culture plate. The sensory neurons were maintained in F-12 
medium containing 30 ng/ml NGF at 3% CO2 in a 37ºC incubator. Growth 
medium was changed every other day.  
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Paclitaxel was reconstituted to 10 mM in MPL and stored at -20ºC. 
Subsequent dilutions of the drug was made in F-12 medium. Unless 
otherwise indicated paclitaxel was added to wells on day 7 in culture. All 
endpoints described in this thesis were examined on day 12. 
 
Neuropeptide release from cell cultures 
Release studies were performed on sensory neuron cultures as 
previously described (Hingtgen and Vasko, 1994). After the medium was 
removed, neuronal cultures were washed once with HEPES buffer 
consisting of 25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2, 
1 mM MgCl2, 3.3 mM D-glucose, and 0.1% bovine serum albumin, pH 7.4. 
Following this initial wash, the neuronal cells were exposed to the 0.4 ml 
HEPES buffer for 10 minutes at 37ºC to establish basal release. To 
stimulate release of CGRP, the neurons were exposed to 0.4 ml HEPES 
buffer containing 30 nM capsaicin at 37ºC for 10 minutes. This 
concentration of capsaicin was chosen because it lies on the linear region 
of the capsaicin concentration vs. iCGRP release curve. Basal release 
was re-established by incubating the cells with 0.4 ml HEPES buffer for 10 
minutes at 37ºC. After completion of the release protocol, the cells were 
lysed by adding 0.4 ml of 0.1M hydrochloric acid to the wells and total 
content of the peptide was measured from this lysate. 
After each 10-min incubation, the buffer was removed and the 
amount of iCGRP was measured by radioimmunoassay. An aliquot (50 - 
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300 µl) of the incubation buffer and 20 µl of the cell lysate was assayed for 
iCGRP. Release of iCGRP was normalized to the total content of CGRP. 
The total content of iCGRP was defined as the sum of CGRP released 
during each of the 3 incubations and the amount in the cell lysate. Basal 
and capsaicin-stimulated release is expressed as the percent of total 
content of iCGRP/10 minutes. Total content of CGRP is reported as 
fmol/well. 
 
Iodindation of CGRP for radioimmunoassay 
The resins used for purification of freshly iodinated peptide, P-4 and 
AG 1-X8 (chloride form) were swollen 24 hours in advance in 1 M acetic 
acid plus 0.1% BSA and 200 mM sodium acetate buffer pH 5.0, 
respectively. The P-4 resin was packed in a plastic column to a height of 
15 cm and AG 1-X8 resins were packed in Pasteur pipettes to a height of 
5 cm. The columns and washed once with 1 M acetic acid plus 0.1% BSA 
and 200 mM sodium acetate buffers respectively. Rat (Tyr27)-αCGRP27-37 
was reconstituted in ddH2O to a concentration of 1mg/ml. The iodination 
reaction mixture consisted of 90 µl potassium phosphate buffer (250 MM), 
10 µl diluted (Tyr27)-αCGRP27-37, 20 µl chloramine-T solution (4.4 mM), 
and 10 µl 125I-Na. The reaction was stopped after 40 seconds by adding 
40 µl sodium metabisulfite (26 mM). The reaction mixture was added to 
the AG 1-X8 column. After the volume of liquid disappeared into the 
column, 500 µl sodium acetate buffer was added to the column to elute 
the iodinated peptide. This was repeated until a total of 4 individual 
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fractions were collected. A 10 µl aliquot of each of the 4 fractions were 
counted on the gamma counter. The fraction with the highest amount of 
radioactivity was passed through the P-4 column for further purification. 
The iodinated peptide was eluted off the P-4 column with 1 M acetic acid 
plus 0.1% BSA and fractions were collected at 5 minute intervals for a 
total of 14 fractions. The amount of radioactivity in 10 µl of each fraction 
was determined. The three fractions with the highest amount of 
radioactivity were tested for non-specific binding. For this, a small aliquot 
of each fraction was diluted to 10,000 counts/100 µl of 200 mM Tris buffer 
and 100 µl added to 400 µl 200 mM Tris buffer in triplicate. To these 
samples, 0.5 ml of 1% Norite charcoal solution in 0.1 M phosphate buffer 
also containing 50 mM NaCl and 1 % bovine serum (pH 7.4) was added. 
The mixture was centrifuged at 3000 x g for 10 minutes in a Beckman-
Coulter AllegraAM 6R centrifuge (Fullerton, CA). The charcoal binds to 
free, unbound radiolabeled CGRP samples. This supernatant was 
decanted to a new tube, and the radioactivity in the supernatant was 
measured by gamma scintillation spectrometry on a 2470 WIZARD2 
automatic gamma counter from Perkin Elmer (Shelton, CT). The fractions 
with the lowest nonspecific binding (less than 1%) were diluted to 
1,000,000 cpm/100 µl, aliquoted, and stored at -20ºC.  
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Radioimmunoassay of iCGRP 
Immunoreactive CGRP (iCGRP) was assayed as previously described 
(Chen et al., 1996). CGRP for standard curves was reconstituted in 50 
mM Tris HCl pH 4.0 and further diluted in CGRP assay buffer pH 7.4 
containing 0.2 M Tris base, 0.1% BSA, and 0.06% Dextran (T70). A 
standard curve with known amounts of CGRP (0-250 fmol) was prepared 
in duplicate for each assay. To each standard and sample being assayed, 
25 µl each of 125I-[0Tyr]-iCGRP27-37 containing approximately 2000 cpm 
and a 1:65,000 dilution of CGRP antibody (a generous gift from M. 
Iadorola, NIH) was added. The samples were incubated for 16-20 h at 4ºC 
to allow the binding between the antibody to the CGRP and CGRP27-37 to 
reach equilibrium. Peptides bound to antibody were separated from 
unbound peptides by adding 0.5 ml of 1% Norite charcoal solution in 0.1 M 
phosphate buffer that also contained 50 mM NaCl, and 1 % bovine serum 
(pH 7.4). The peptides were then centrifuged at 3000 x g for 10 minutes. 
Unbound peptide is trapped by the charcoal, while the supernatant 
contains antibody bound to peptide (radiolabeled or unlabeled). The 
supernatant was decanted to a new tube, and the radioactivity was 
measured by gamma scintillation spectrometry. The amount of iCGRP in 
perfusate samples was quantified by comparing the radioactivity in 
samples to those values in a standard curve using a 4 point non-linear 
least squares regression analysis. Using this method, the minimal 
detectable amount of iCGRP was 10 fmoles (95% confidence interval). 
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Western blot and densitometry 
For immunoblotting of proteins from sensory neurons in culture, 
cells were scraped in cold PBS using a cell scraper and centrifuged at 
14,000 x g at 4°C for 10 minutes in an Eppendorf Centrifuge 5415R 
(Hauppauge, NY). The pelleted cells were resuspended in modified RIPA 
lysis buffer containing 50 mM Trizma base, 150 mM NaCl, 1% NP-40, 
0.25% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 µg/ml 
pepstatin, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM Na3VO4, and 25 mM 
NaF. The cells were sonicated on ice for 10 seconds using a 559 Sonic 
Dismembrator from Fisher Scientific (Pittsburg, PA). The lysate was 
centrifuged at 14000 x g at 4ºC, and the pellet containing membrane 
fragments was discarded. The supernatant consisting of cytoplasmic and 
membrane proteins was assayed for protein content by the Bradford 
assay. This assay is a dye-binding assay in which a differential color 
change of a dye (Coomassie® Brilliant Blue G-250) occurs in response to 
varying concentrations of protein. The absorbance maximum for the dye is 
465 nm, which shifts to 595 nm after it binds to protein. 
To determine protein concentration in each lysate, a standard curve 
was prepared with 0-500 µg/ml bovine IgG protein; 10 µl of each standard 
or diluted lysate was added into separate microtiter wells of a 96-well 
plate. 200 µl of the diluted dye reagent (1ml dye + 4 ml ddH2O) was added 
to each well. The dye was allowed to react with the protein at room 
temperature for 5 minutes. The absorbance at 560 nm of the samples was 
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determined using a Tecan SpectraFluor Plus spectrophotometer with 
Magellan 5.03 software (Crailsheim, Germany). Linear regression analysis 
of the graph of absorbance vs. concentration of standard was used to 
calculate the concentration of protein in the cell lysates.  
Approximately 20 µg of the protein was loaded on precast bis-Tris 
polyacrylamide gels and run at 200 mV for 30 minutes. The proteins on 
the gel were transferred to a polyvinylidene fluoride (PVDF) membrane 30 
mV for 1 hr. The membrane with transferred proteins was washed once 
with ddH2O and blocked for 1 hour with 5% donkey serum in Tris buffered 
saline containing 0.1% tween 20 (TBST). The membrane was incubated 
overnight at 4ºC with a 1:500 dilution of the TRPV1 antibody in 5% donkey 
serum. The blot was washed 3 times with TBST, each time for 10 minutes. 
Next, the blot was incubated with a 1:10000 dilution of a goat anti-donkey 
antibody coupled to horseradish peroxidase (HRP) for 1 hour at room 
temperature. After washing off the secondary antibody 3 times with TBST 
for 10 minutes per wash, the blot was incubated with Western Lightning® 
chemiluminescent substrate solution, exposed to light sensitive 
radiographic film, and developed.  
Before immunoblotting for actin, the membrane was stripped off all 
bound antibodies, washed with TBST and blocked with 5% donkey serum 
for 1 hour at room temperature. Anti-actin antibody (1:5000) was 
incubated with the blot for 1 hour. Excess antibody was washed off with 
TBST for 30 minutes (10 minutes x 3 times). HRP conjugated secondary 
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antibody in 5% donkey serum (anti-mouse) was allowed to incubate with 
the blot for 1 hour at room temperature. The secondary antibody was 
washed off the blot by rinsing with TBST 3 times for 10 minutes each. The 
blot was then exposed to chemiluminescent substrate and developed as 
mentioned above.  
 
Optimization of the Western blot to examine TRPV1 immunoreactivity 
Proteins were extracted as outlined above. To confirm antibody specificity 
for TRPV1, a lysate of DRG cells in culture was analyzed by western blot. 
using neutralized TRPV1 antibody. For these experiments, 20 µgs of 
sensory neuron lysate, lysates of Chinese hamster ovary (CHO) cell over-
expressing TRPV1 (positive control), and CHO cell lysate not expressing 
TRPV1 (negative control) were loaded in duplicates on two gels and 
separated by electrophoresis as described above. The gels were 
transferred to a PVDF membrane and blocked with 5% donkey serum in 
TBST at room temperature for 1 hour. Meanwhile, a 1:500 dilution of the 
anti-TRPV1 antibody in 5% donkey serum was incubated with the blocking 
peptide (1 part antibody + 4 parts blocking peptide) for 1 hour on a rocking 
platform to neutralize the antibody. One of the two blots was incubated 
with the neutralized antibody, while the other was blotted with non-
neutralized anti-TRPV1 antibody. Both membranes were allowed to 
incubate overnight at 4ºC, washed, and then incubated with the secondary 
antibody as before. The blots were exposed to chemiluminescent 
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substrate and developed. The results are shown in Figure 7. The 
membrane incubated with anti-TRPV1 antibody revealed a band migrating 
at ≈98 kD in the sensory neuron lysate and TRPV1-expressing CHO cell 
lysate but not in the non-TRPV1 expressing CHO cell lysate (Figure 7, left 
panel). Furthermore, the antibody did not recognize any bands in the lane 
containing the negative control (non-TRPV1 expressing CHO cell lysate). 
No immunoreactivity for TRPV1 was detected in the membrane blotted 
with neutralized antibody (Figure 7, right panel). These data confirm that 
the band migrating at 98 kD is immunoreactive for TRPV1.  
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Figure 7. Identification of the immunoreactive TRPV1 band. The left panel 
is the PVDF membrane that was blotted with anti-TRPV1 antibody. The 
right panel represents the membrane that was blotted with neurtralized 
anti-TRPV1 antibody. Lanes 1, 2 and 3 were loaded with lysates from 
sensory neurons, CHO cells over-expressing TRPV1 (positive control), 
and non-TRPV1 expressing CHO cells (negative control). 
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Real Time polymerase chain reaction 
 
Extraction of RNA 
Total RNA was extracted from sensory neuronal cultures using the 
PrepEase® RNA Spin Kit according to the instructions supplied. Total 
RNA was quantified using the Nanodrop ND1000 spectrophotometer from 
Thermo Fisher Scientific (Wilmington, DE); 1 OD unit at 260 nm = 40 
µg/ml of RNA. The RNA yield was considered pure if the 260/280 nm 
absorbance ratio was of 1.9-2.2 units.  
 
Reverse transcription of RNA to cDNA 
cDNA was synthesized from 1 µg of RNA using a Bio-Rad 
Laboratories' iScript cDNA Synthesis Kit. The reaction mixture consisted 
of 1 µg RNA, 4 µl of the iScript reaction mix, and 1 µl of iScript reverse 
transcriptase and nuclease free water so that the total volume of each 
reaction was 20 µl. Using a MultiGene® thermocycler from Labnet 
International, INC (Edison, NJ), the reverse transcriptase reaction was 
performed for 5 minutes at 25°C, for 30 minutes at 42°C, then for 5 
minutes at 85ºC.  
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Validation of the 2-ΔΔCT method for relative quantification 
Quantification of mRNA for specific genes was performed by the  
2-∆∆CT method. For this method to be valid, the amplification 
efficiency of the primer-probe sets for the target sequence (TRPV1 or 
Nav1.9) must be identical to that of the endogenous control 
(Glyceraldehyde 3-phosphate dehydrogenase - GAPDH). The efficiencies 
can be determined by looking at how ∆CT varies with template dilution 
(Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). The CT 
(threshold cycle) for the target gene is subtracted from the CT for GAPDH: 
this value is referred to as the ∆CT value. If the slope of ∆CT (absolute 
value) versus cDNA dilution is close to zero, it implies that the efficiencies 
of the target and housekeeping genes are very similar, and the 2-∆∆CT 
method can be used for relative quantification.  
A standard curve was prepared using 0.01 to 100 ngs of cDNA in 
10 fold increments. Each dilution of cDNA was amplified in 2 sets of 
triplicates: one set contained 1 µl/well of the probe-primer mix for the 
target gene, and the other set contained 1 µl/well of the probe and primer 
mix for GAPDH. Each well also contained 10 µl of the TaqMan master 
mix. The real time PCR reaction was performed in a StepOne Plus® 7500 
Fast Real-Time PCR system from Applied Biosystems (Foster City, CA) 
using universal amplication parameters. Figures 8 and 9 show the 
absolute value of the slope of ∆CT vs concentration of cDNA as less than 
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0.1 and close to 0. Therefore the 2-∆∆CT can be used for relative 
quantification of TRPV1 or Nav 1.9. 
 
Relative quantification of TRPV1 or Nav1.9 from paclitaxel-treated sensory 
neurons in culture  
For quantification of mRNA (TRPV1 or Nav1.9) from paclitaxel-
treated cells, RNA isolation and cDNA synthesis were performed as 
already described. For the relative quantification reaction, 30 ngs of cDNA 
per well was used as the template. Each sample was amplified in 2 sets of 
triplicates; one set for target gene amplication and the other for GAPDH. 
The rest of the procedure was identical to the one above. The mean ± 
SEM of the expression of mRNA for TRPV1 or Nav1.9 expressed as % of 
untreated control was compared by one-way ANOVA and Bonferroni’s 
post test.  




Figure 8. Validation of the 2-ΔΔCT method for relative quantification of 
TRPV1. Different cDNA dilutions synthesized from total RNA from isolated 
sensory neurons were amplified. The efficiency of amplification of TRPV1 
and GAPDH was examined using real-time PCR and TaqMan detection. 
The ΔCT (CT,TRPV1 - CT,GAPDH) was calculated for each cDNA concentration. 
The data were fit using least-squares linear regression analysis. 
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Figure 9. Validation of the 2-ΔΔCT method for relative quantification of 
Nav1.9. Different cDNA dilutions synthesized from total RNA from isolated 
sensory neurons were amplified. The efficiency of amplification of Nav1.9 
and GAPDH was examined using real-time PCR and TaqMan detection. 
The ΔCT (CT,Nav1.9 - CT,GAPDH) was calculated for each cDNA concentration. 
The data were fit using least-squares linear regression analysis. 
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Propidium iodide (PI) and annexin V double labeling 
Viability of sensory neurons following exposure to paclitaxel was 
assessed by double staining with PI and annexin V. Sensory neuronal 
cultures were exposed to either 300 nM or 1 µM paclitaxel for 2 or 5 days. 
As a positive control, untreated neurons were exposed to 300 µM H2O2 for 
1 hour at 37ºC (Vasko et al., 2005). At the end of the 1-hour incubation the 
neurons were returned to F12 medium. Approximately 24 hours later, all 
neurons were incubated with 0.4 ml of the staining solution containing 25 
µl annexin V - FITC in 10 ml HEPES buffer and 6 µM PI. After washing off 
the staining solution, cells were visualized. The excitation of PI/annexin V 
was 530/485 nm and the emitted light was monitored at 645/530 nm. PI is 
a DNA intercalating agent that is only able to penetrate the membrane of 
dead cells. Annexin V has high affinity for phosphatidylserine (PS), which 
is located in the inner (cytoplasmic) leaflet of the cell membrane. Following 
induction of apoptosis, PS is translocated to the outer (cell surface) leaflet 
of the cell membrane, where it is now easily accessible to annexin V in the 
staining solution. After staining with PI and annexin V nuclei appear red 
while cells that are in the initial stages of apoptosis display a green 
colored ring around the cells. Dead cells more diffused staining with 
annexin V. Neurons in five random fields were counted and scored as 
either viable (unstained) or non-viable (red or green). The data were 
expressed as mean ± SEM % of total number of neurons counted.  
	   	   	   	   	   69 
Biolistic transfection of neurons for assessment of neurite length 
The biolistic transfection method utilized the Helios Gene Gun 
System from Bio-Rad Laboratories (Hercules, CA, U.S.A). Optimized 
protocols were designed and modified from a recently published report 
(Dib-Hajj et al., 2009) and from the manufacturer’s instructions (Bio-Rad 
Laboratories Helios Gene Gun System) to increase efficiency and 
preserve the health of neurons. Briefly, a 24 inch piece of tubing was cut 
to fit the saddle of the Tubing Prep Station, and ultrapure grade nitrogen 
was allowed to flow (0.3-0.4 LPM) through the plastic tubing for 
approximately 20 minutes to purge ambient oxygen and completely dry 
the interior of the tubing. A 15 mg (1:1 ratio of mg gold to µg cDNA) aliquot 
of gold microcarriers (1 µm size) was weighed. Fresh aliquots were made 
of PVP and spermidine in fresh, high grade (dehydrated) ethanol (EtOH) 
from stock solutions of 20 mg/mL and 1 M, respectively, and were stored 
at -20ºC. The final concentrations of PVP and spermidine aliquots used for 
the experiment were 0.05 mg/ml and 0.05 M respectively. 
For transfection of rat DRG neurons, 10 µg of cDNA for enhanced 
green fluorescent protein (EGFP) in a volume of 10 µl was used. 
Spermidine (0.05 M), CaCl2 (1M) and cDNA were used at a 1:1:1 ratio. 
First, spermidine was added to the gold microcarriers and the complex 
was vigorously mixed by vortex and sonicated to break up large particles. 
cDNA was then added to this suspension and mixed. Next, 1M CaCl2 was 
added drop-wise to the slurry of gold particles on the vortex. The complex 
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was allowed to sit for 10 min before centrifuging to remove the volume. 
The gold-DNA pellet was then washed and reconstituted three times with 
dehydrated EtOH. After the last EtOH wash, the gold-DNA complex was 
reconstituted using the entire volume of the PVP aliquot and transferred to 
a 15 mL conical tube. The contents of the conical tube were drawn into the 
nitrogen-purged tubing using a syringe and were carefully placed back into 
the tubing prep station saddle. The complex rested undisturbed in the 
tubing for approximately 3-5 minutes before the liquid (EtOH) contents 
were slowly removed with a syringe at a rate of 0.5-1.0 in/sec, after which 
the automatic rotation of the plastic tubing was started. Next, the nitrogen 
was turned back on at a flow of 0.3-0.4 LPM for approximately 20 min. 
Cartridges were cut and placed into the Helios Gene Gun cartridge holder 
and contents were shot using the helium pressure within the gene gun 
onto 6-well plates containing recently harvested (~24 hrs) rat DRG 
neurons. The pressure and velocity was chosen so as to achieve 
transfection in only a few neurons while not affecting the health of the 
neurons. Transfected neurons expressed EGFP, and green fluorescence 
was visible as early as 24 hrs post-transfection. Shown in Figure 10 is a 
neuron that stably expresses EGFP. 






Figure 10. Sensory neuron expressing EGFP 48 hours after transfection 
using the gene gun method.  
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The neurons were photographed immediately before exposure to 
paclitaxel on day 7 in culture, and again 2 and 5 days (day 9 and day 12 in 
culture, respectively) after exposure to 10, 100 or 300 nM paclitaxel. The 
images were analyzed with the help of the neurite outgrowth plug-in, 
which was compatible with the MetaMorph 7.6 software. This software 
measures total outgrowth of the neuron projecting from the cell body 
rather than the length of individual neurites. User-defined criteria, such as 
detection threshold and diameter of cell body, were used to quantify length 
of processes. The validity of the specified criteria can be verified by 
observing traces superimposed by the software onto the original image for 
purposes of comparison. Data were expressed as % change in the length 
of neurites on day 9 and on day 12 relative to that on day 7.  
 
Data Analysis 
All data were analyzed using Prism 4.0 by GraphPad. Unless otherwise 
indicated, statistical significance was established using one-way ANOVA 
with Bonferroni’s post test, p < 0.05. 
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RESULTS 
 
Capsaicin increases blood flow in a concentration dependent manner 
There are several reports that activation of sensory neurons causes 
release of CGRP in the periphery resulting in vasodilatation (Brain et al., 
1985; Brain et al., 1986; Kilo et al., 1997). Consequently, examination of 
cutaneous vasodilatation after activation of small diameter sensory 
neurons can be used as an indirect method to measure the release of 
CGRP from peripheral nerve endings of these neurons. We performed an 
initial series of experiments to establish a model for capsaicin-induced 
neurogenic vasodilatation in a manner analogous to previous studies 
(Buckley et al., 1990; Hughes and Brain, 1991; Escott and Brain, 1993). 
We initially established that intradermal injection of capsaicin could 
increase cutaneous blood flow (Figure 4B).  
To find a concentration of capsaicin that lies on the linear region of 
the concentration vs. vasodilatation curve, I recorded changes in blood 
flow in response to 1 µl of different concentrations of capsaicin. The 
capsaicin-evoked response was plotted against the concentration of 
capsaicin to generate the dose response curve. The evoked response was 
calculated by subtracting the basal blood flow recorded in the presence of 
the needle for 15 minutes from the blood flow recorded for fifteen minutes 
after injection of capsaicin. The evoked response at different 
concentrations of capsaicin is listed in Table 2. 






(tissue perfusion units) 
0 9.9 ± 3.3 
300 nM 91.4 ± 14.4 
1 µM 123.4 ± 13.7 
3 µM 166.5 ± 6.8 
10 µM 175.5 ± 25.1 
30 µM 253.3 ± 21.2 
100 µM 295.8 ± 20.8 
300 µM 321.7 ± 20.9 
1 mM 281.8 ± 35.6 
 
Table 2. Evoked response/15 minutes at different concentrations of 
capsaicin. 
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Figure 11 illustrates that capsaicin induces vasodilatation in a 
concentration-dependent manner. The EC50 (12 µM) was calculated 
using a 4-point non-linear least squares regression analysis. Since 10 
µM lies on the linear region, all future experiments on capsaicin-evoked 
cutaneous vasodilatation were performed with this concentration.  





Figure 11. Intradermal injection of capsaicin increases cutaneous blood 
flow in dose dependent manner. Each point is the mean ± SEM of evoked 
blood flow in TPU/15 min for vehicle (0.01% MPL in PBS) or various 
concentrations of capsaicin injected intradermally in the hind paws of rats. 
The data were fit using 4 point non-linear least squares regression 
analysis. The EC50 was 12 µM. 
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 To demonstrate that the capsaicin-induced vasodilatation is 
mediated by CGRP, I determined whether the CGRP1 receptor antagonist 
CGRP8-37 could attenuate the effects of capsaicin. For these experiments, 
two 30 gauge needles were glued together, each needle was connected 
via tubing to two different syringes; one syringe was filled with capsaicin 
(10 µM) and the other with CGRP8-37 (20 µM). This way CGRP8-37 and 
capsaicin can be injected at the same site. After the initial baseline was 
recorded, the needle was inserted intradermally and a second baseline 
was recorded for fifteen minutes. As can be seen in Figures 11 and 12, 
insertion of the needle did not significantly alter blood flow. When 10 µM 
capsaicin was injected intradermally, blood flow increased from 11.7 ± 1.9 
to 25.4 ± 3.2 TPU/ 3 minutes. However, when the CGRP receptor 
antagonist was injected 5 minutes before capsaicin, there was no change 
in blood flow. The response recorded before injection of CGRP8-37 was 
16.6 ± 1.9 and after injection of capsaicin was 14.0 ± 20 TPU/3 minutes 
(Figure 12B). Additionally, intradermal injection of CGRP8-37 or vehicle (0.1 
% MPL in PBS) alone did not alter baseline blood flow. Blood flow 
recorded before injection of the antagonist was 13.3 ± 4.6 and after 
injection was 12.9 ± 2.2 TPU/3 minutes (Figure 13A). Blood flow before 
and after injection of vehicle was 14.0 ± 1.3 and 14.3 ± 1.3 TPU/ 3 
minutes (Figure 13B).  
As discussed in the methods, the mean ± SEM of the evoked 
response over a 15-minute period was compared. Figure 14 A shows that 
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blood flow over 15 minutes increased from 53 ± 7 TPU/15 min to 121 ± 15 
TPU/15 min after intradermal injection of capsaicin. In the presence of 
CGRP8-37 and capsaicin, blood flow was 74 ± 9 TPU/15 min before 
capsaicin and 70 ± 11 TPU/15 min after injection of capsaicin, suggesting 
that CGRP8-37 blocked the vasodilatation by capsaicin. The capsaicin-
evoked blood flow was 68 ± 11 TPU/15 minutes in the absence of the 
CGRP8-37, whereas in the presence of CGRP8-37 the evoked response was 
-4 ± 5 TPU/15 minutes (Figure 14B).  
CGRP8-37 at the concentration used in our study (20 µM) did not by 
itself alter blood flow. The basal blood flow before and after injection of the 
antagonist was 63 ± 21 and 58 ± 10 TPU/ 15 min respectively (Figure 
14C) and the evoked response was -4 ± 13 TPU/15 min (Figure 14D). 
This suggests that there is no tonic control of blood flow by CGRP in our 
preparation. Furthermore injection of the vehicle did not alter basal blood 
flow. The blood flow recorded before and after intradermal injection of 
vehicle was 68 ± 6 TPU/15 min and 70 ± 10 TPU/15 min respectively 
(Figure 14C), and the evoked response was 2 ±11 TPU/15 minutes 
(Figure 14D). Together, these data demonstrate that the increase in blood 
flow caused by capsaicin is mediated by CGRP.  
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Figure 12. The CGRP receptor antagonist, CGRP8-37, blocks capsaicin-
induced cutaneous vasodilatation. Each column represents the mean ± 
SEM. The open columns and the light columns represent basal blood flow 
before and after intradermal insertion of the needle, respectively. The dark 
columns represent blood flow after injection of vehicle (0.01% MPL in 
PBS) then 10 µM capsaicin (A) or 20 µM CGRP8-37 then 10 µM capsaicin 
(B). 




Figure 13. The CGRP receptor antagonist, CGRP8-37 or the vehicle (0.01% 
MPL in PBS) do not alter blood flow. E, Each column represents the mean 
± SEM. The open columns and the light columns represent basal blood 
flow before and after intradermal insertion of the needle respectively. The 
dark columns represent blood flow after injection of CGRP8-37 before 
vehicle (0.01% MPL in PBS) (A) or vehicle before a second injection of 
vehicle (B). 




Figure 14. The capsaicin-evoked response in presence of CGRP8-37 is 
significantly different from that recorded in presence of the vehicle. Each 
column is the mean ± SEM. Lightly shaded represent TPU recorded for 15 
minutes following placement of the needle. Dark columns represent TPU 
recorded for 15 minutes following injection of capsaicin ± CGRP8-37 (A) or 
vehicle ± CGRP8-37 (C). Capsaicin-evoked response is statistically higher 
in absence of CGRP8-37 (B). Capsaicin-evoked response in presence of 
vehicle was not different from that in presence of CGRP8-37 (D). An 
asterisk indicates statistical significance by one-way ANOVA with 
Bonferroni’s post tests, p < 0.05.  
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Electrical stimulation mediated cutaneous vasodilatation is mediated by 
CGRP 
 It has been demonstrated by Luo et al., that human umbilical 
vascular endothelial cells in culture synthesize and release CGRP after 
exposure to capsaicin (Luo et al., 2008). Therefore it is possible that the 
cutaneous vasodilatation mediated by capsaicin is secondary to release of 
CGRP from endothelial cells. To demonstrate vasodilatation after direct 
activation of sensory neurons, the sciatic nerve was stimulated using an 
electrical stimulus. The sciatic nerve arises from the lumbar ganglia L4, 
L5, and L6, and it innervates the hind paw of the rat (Takahashi et al., 
2003). Koltzenburg et al., showed that electrical stimulation of the sciatic 
nerve using a stimulus intensity of 5 mA at 10 Hz for 30 seconds activates 
not only the large low threshold sensory neurons but also the high 
threshold and slowly-conducting unmyelinated C fibers and the thinly-
myelinated Aδ fibers including those containing CGRP (Koltzenburg et al., 
1990). Therefore this stimulus intensity was used to activate sensory 
neurons and induce vasodilatation in the skin. 
After recording basal blood flow for 10 minutes, the trunk of the sciatic 
nerve was transected at the mid-thigh level (Figure 5). In the initial 
experiments, I observed a significant increase in basal blood flow after 
transection, which was likely due to action potential discharges initiated by 
the injury (data not shown). Therefore, 1% lidocaine was applied distal to 
the stimulation site immediately prior to cutting the sciatic nerve. After 
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placing the stimulator on the sciatic nerve, the animal was sutured and 
allowed to recover for 30 minutes before application of the electrical 
stimulus.  
As can be seen from Figure 15A, electrical stimulation of the sciatic 
nerve significantly increased blood flow from 20 ± 3 to 64 ± 1 TPU/3 
minutes. The response over 15 min increased from a basal value of 103 ± 
15 TPU/15 minutes to 329 ± 8 TPU/15 minutes (Figure 16A). The increase 
in blood flow was maintained for at least 30 minutes after the 30-second 
stimulation. The average evoked response (obtained by subtracting the 
basal response from the response after stimulation) was 226 ± 19 TPU/15 
minutes (Figure 16B).  
To determine if the increase in blood flow by electrical stimulation was 
mediated by CGRP released from sensory neurons, CGRP8-37 was 
injected into the paw prior to electrical stimulation of the sciatic nerve. In 
the presence of 20 µM CGRP8-37, electrical stimulation did not result in a 
significant increase in blood flow over time. Basal blood flow was 23 ± 2 
TPU/3 minutes, while stimulated blood flow in the presence of CGRP8-37 
was 24 ± 2 TPU/3 minutes (Figure 15B).  
Figure 16A shows that basal blood flow before electrical stimulation 
was 112 ± 8 TPU/15 minutes, and after stimulation in the presence of 
CGRP8-37 was 126 ± 11 TPU/15 minutes. The evoked response in the 
presence of CGRP8-37 was 14 ± 10 TPU/15 minutes, which was 
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significantly lower than that recorded in the absence of the CGRP8-37 (226 
± 19 TPU/15 minutes, Figure 16B).  
Together, these data suggest that the increase in blood flow by 
electrical stimulation of the sciatic nerve is mediated by CGRP released 
from the peripheral endings of sensory neurons.  
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Figure 15. CGRP8-37 blocks electrical stimulation-evoked cutaneous 
vasodilatation. Each column represents the mean ± SEM. The open 
columns and the light columns represent basal blood flow before and after 
axotomy respectively. Dark columns represent blood flow changes after 
electrical stimulation preceded either by intradermal vehicle (A) or by 
intradermal CGRP8-37 (B).  
 
 







Figure 16. The electrical stimulation-evoked cutaneous vasodilatation is 
dependent on CGRP. Each column is the mean ± SEM. Lightly shaded 
represent TPU recorded for 15 minutes following axotomy while dark 
columns represent TPU recorded after electrical stimulation ± CGRP8-37 
(A). Responses evoked by electrical stimulation are decreased when 
CGRP8-37 is injected before stimulation (B). An asterisk indicates statistical 
significance by one-way ANOVA with Bonferroni’s post tests, p < 0.05.  
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Chronic administration of paclitaxel reduces sensory neuron mediated 
cutaneous vasodilatation 
To determine if paclitaxel alters the release of CGRP from sensory 
neurons, we measured the ability of capsaicin or electrical stimulation to 
vasodilate after chronic administration of the microtubule-stabilizing drug. 
As demonstrated above, cutaneous vasodilatation induced by activation of 
sensory neurons is mediated by CGRP, hence as an indirect measure of 
CGRP release we measured changes in blood flow after stimulation of 
peripheral endings of sensory neurons. Male Sprague Dawley rats were 
injected with 1 mg/kg paclitaxel every other day for a total of 4 doses, and 
vasodilatation was examined 2 weeks after the first injection.  
In vehicle injected animals, injection of 10 µM capsaicin in 1 µl 
increased blood flow from 18 ± 1 to 56 ± 3 TPU/ 3 minutes (Figure 17A). 
The blood flow over 15 minutes increased from 88 ± 4 to 277 ± 19 TPU/15 
minutes (Figure 18A), which represents an evoked release of 190 ±19 
TPU/ 15 minutes (Figure 18B). In contrast, in rats injected with 1 mg/kg 
paclitaxel every other day for a week, and studied one week after the last 
injection, 10 µM capsaicin increased blood flow from 17 ± 1 to 31 ± 4 TPU/ 
3 minutes (Figure 17B). The increase over 15 minutes was 158 ± 16 TPU 
from 82 ± 6 TPU/15 minutes (Figure 17A). The evoked blood flow was 76 
± 17 TPU/15 minutes, which was significantly lower than that in vehicle 
treated rats (Figure 17B). 
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Paclitaxel also decreased vasodilatation induced by electrical 
stimulation of the sciatic nerve. Stimulation of the sciatic nerve in vehicle-
treated animals produced more than a 3-fold increase in blood flow over 
baseline; blood flow increased from 26 ± 5 to 85 ± 5 TPU/3 minutes in 
(Figure 19A). Over a period of 15 minutes, the blood flow increased from 
128 ± 21 to 426 ± 24 TPU/15 min (Figure 20A), and the evoked response 
was 298 ± 30 TPU/15 minutes. In animals that were injected with 
paclitaxel, the increase in blood flow after electrical stimulation was 30 ± 4 
to 56 ± 5 TPU/ 3 minutes (Figure 19B). Over 15 minutes, the blood flow 
increased from 145 ± 19 to 296 ± 28 TPU (Figure 20A), which represents 
an evoked response of 151 ± 13 TPU/15 minutes (Figure 20B).  
In summary, paclitaxel decreased cutaneous vasodilatation 
mediated by activation of sensory neurons. Because cutaneous 
vasodilatation is mediated by CGRP, these data suggest that paclitaxel 
decreases the release of CGRP from small diameter sensory neurons. 




Figure 17. Chronic administration of paclitaxel decreases capsaicin-
induced cutaneous vasodilatation in the rat hind paw. Each column 
represents the mean ± SEM. The open columns and the light columns 
represent basal blood flow before and after intradermal insertion of the 
injection needle, respectively. The dark columns represent blood flow after 
injection of 10 µM capsaicin in rats chronically administered with vehicle 
(A) or 1 mg/kg paclitaxel (B). 
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Figure 18. The capsaicin-evoked vasodilatation is significantly attenuated 
in paclitaxel-injected animals. Each column is the mean ± SEM. A: Lightly 
shaded represent TPU recorded for 15 minutes following placement of the 
needle. Dark columns represent TPU recorded for 15 minutes following 
injection of capsaicin in vehicle or paclitaxel-treated animals B: Capsaicin-
evoked blood flow over 15 minutes in vehicle or paclitaxel-injected 
animals. In A and B, an asterisk indicates statistical significance between 
the paclitaxel-treated group and the vehicle-injected group by one-way 
ANOVA with Bonferroni’s post tests, p < 0.05.  
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Figure 19. Chronic administration of paclitaxel decreases electrical 
stimulation-induced cutaneous vasodilatation in the rat hind paw. Each 
column represents the mean ± SEM. The open and light shaded columns 
represent the basal blood flow before and after axotomy respectively. The 
dark columns represent blood flow after electrical stimulation of the sciatic 
nerve in rats that were administered vehicle (A) or paclitaxel (B). 
 
 






Figure 20. The electrical stimulation-evoked vasodilatation is significantly 
attenuated in paclitaxel-injected animals. Each column is the mean ± 
SEM. A: Lightly shaded represent TPU recorded for 15 minutes before 
stimulation. Dark columns represent TPU recorded for 15 minutes 
following electrical stimulation. B: Electrical stimulation-evoked changes in 
blood flow over 15 minutes in vehicle or paclitaxel-injected animals. In A 
and B, an asterisk indicates statistical significance between the paclitaxel-
treated group and the vehicle-injected group by one-way ANOVA with 
Bonferroni’s post tests, p < 0.05.  
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Chronic administration of paclitaxel does not affect vasodilatation-induced 
by intradermal injection of CGRP or methacholine 
While it is possible that the decreased vasodilatation results from 
decrease in sensory neuron function, altered expression or function of the 
CGRP1 receptor on blood vessels could also contribute to the attenuation 
in sensory neuron mediated increase in skin blood flow. Therefore 
vasodilatation in response to intradermal injection of CGRP was examined 
in paclitaxel-treated rats.  
In vehicle treated animals, blood flow increased from 20 ± 2 to 60 ± 
2 TPU/3 minutes (Figure 21A). Over 15 minutes the blood flow increased 
from 97 ± 11 to 316 ± 14 TPU (Figure 22A), the evoked response was 219 
± 8 TPU/ 15 minutes (Figure 22B). In paclitaxel-injected animals, the blood 
flow increased from 20 ± 3 to 59 ± 1 TPU/3 minutes (Figure 21B). Over 15 
minutes, the blood flow increased from 96 ± 15 to 302 ± 8 TPU (Figure 
22A), which represents an evoked response of 206 ± 15 TPU/15 minutes 
(Figure 22B). Paclitaxel did not alter the ability of blood vessels to dilate in 
response to intradermal CGRP, suggesting that the expression or function 
of the CGRP receptor was not altered in paclitaxel injected animals. 
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Figure 21. Chronic administration of paclitaxel does not alter CGRP-
induced cutaneous vasodilatation. Each column represents the mean ± 
SEM. The open columns and the light columns represent basal blood flow 
before and after intradermal placement of the needle, respectively. The 
shaded columns represent blood flow after injection of 30 µM CGRP in 
either vehicle (A) or paclitaxel-injected animals (B). 





Figure 22. Vasodilatation evoked by intradermal CGRP is not altered in 
paclitaxel-injected animals. Each column represents the mean ± SEM. A: 
Lightly shaded columns represent TPU recorded for 15 minutes after 
intradermal placement of the needle. Dark columns represent TPU 
recorded for 15 minutes following injection of CGRP. B: CGRP-evoked 
changes in blood flow over 15 minutes in vehicle or paclitaxel-injected 
animals.  
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 To determine whether paclitaxel interferes with smooth muscle 
relaxation, vasodilatation was examined in response to methacholine, the 
muscarinic receptor agonist. Methacholine induces vasodilatation in a 
nitric oxide-dependent manner (Kimura et al., 2007). When injected 
intradermally in vehicle-injected animals, 100 µM methacholine caused a 
significant increase in blood flow from 20 ± 2 to 53 ± 3 TPU/3 minutes 
(Figure 23A). Over a period of 15 minutes, methacholine increased blood 
flow from 97 ± 8 to 276 ± 11 TPU (Figure 24A), the evoked response in 
this case was 179 ± 15 TPU/15 minutes (Figure 24B). In paclitaxel 
injected animals, intradermal injection of 100 µM methacholine caused an 
increase in blood flow over 3 minutes from 18 ± 2 to 56 ± 5 TPU (Figure 
23B). Over 15 minutes, the blood flow increased from 88 ± 8 to 290 ± 23 
TPU (Figure 24A). The evoked response was 201 ± 23 TPU/15 minutes 
(Figure 24B). These data demonstrate that paclitaxel does not inhibit the 
ability of the vascular smooth muscle to relax and produce vasodilatation. 
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Figure 23. Chronic administration of paclitaxel does not alter 
methacholine-induced cutaneous vasodilatation. Each column represents 
the mean ± SEM. The open columns and the light columns represent 
basal blood flow before and after intradermal placement of the injection 
needle, respectively. The dark columns represent blood flow after injection 
of 100 µM methacholine in either vehicle injected animals (A) or paclitaxel 
injected animals (B). 
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Figure 24. Vasodilatation evoked by intradermal methacholine is not 
altered in paclitaxel-injected animals. Each column represents the mean ± 
SEM A: Lightly shaded columns represent TPU recorded for 15 minutes 
after placement of needle. Dark columns represent TPU recorded for 15 
minutes after injection of methacholine B: Methacholine-evoked changes 
in blood flow over 15 minutes in vehicle or paclitaxel-injected animals.  
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Chronic administration of paclitaxel does not alter the release of iCGRP 
from dorsal spinal cord 
Microtubules participate in the transport of organelles and vesicles 
from the cell body to the nerve ending since inhibition of microtubule 
function has been shown to interfere with axonal transport (Banks et al., 
1971b; Banks et al., 1971a; Mayor et al., 1972; Smith et al., 1975; Heiwall 
et al., 1978; Nakata and Yorifuji, 1999; Theiss and Meller, 2000). Thus, it 
is possible that paclitaxel decreases the content of CGRP and 
consequently the release of the neuropeptide at all nerve endings of the 
sensory neurons. To examine this, CGRP content and release was 
directly quantified from the central terminals of small diameter sensory 
neurons in spinal cord slices from paclitaxel-injected rats. 
Slices were prepared from the dorsal lumbar region of the spinal 
cord because this region is enriched with sensory nerve endings that 
innervate the hind paws of the rat. As can be seen in Figure 25A and B, 
treating rats with paclitaxel did not alter basal release of iCGRP compared 
to rats treated with vehicle. Before stimulation, the amount of CGRP 
released in slices from vehicle injected animals was 0.77 ± 0.1 % total 
content/9 minutes while that from paclitaxel injected animals was 0.67 ± 
0.07 % content/9 minutes (Figure 26A). After stimulation with 500 nM 
capsaicin CGRP release increased to 4.5 ± 0.5 % content/9 minutes and 
3.6 ± 0.5 % content/9 minutes in vehicle or paclitaxel injected animals 
respectively (Figure 26A) giving an evoked release of 3.8 ± 0.5 % 
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content/9 minutes and 2.9 ± 0.5 % content/9 minutes in the vehicle-
injected group and the paclitaxel-injected group respectively (Figure 26B). 
The total content of iCGRP in the tissue from vehicle-injected animals was 
505.9 ± 33.8 and that from paclitaxel-treated animals was 496.8 ± 30.6 
fmol/mg of tissue (Figure 26C).  
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Figure 25. Chronic administration of 1 mg/kg paclitaxel does not alter 
capsaicin-evoked iCGRP release from rat spinal cord slices. Each column 
represents the mean ± SEM. The horizontal bar indicates the time when 
the tissues were exposed to capsaicin. iCGRP release in each 3-minute 
perfusion sample is expressed as percent of total peptide content per 
minute. A: iCGRP release in slices taken from vehicle-treated rats, B: 
iCGRP release in slices taken from paclitaxel-injected rats. 
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Figure 26. Capsaicin-evoked release of iCGRP is not altered in paclitaxel-
treated animals. Each column is the mean ± SEM. A: Basal release is the 
sum of the 3 collections prior to capsaicin, whereas capsaicin-stimulated 
release is the sum of the three collections in the presence of capsaicin B: 
Evoked release of iCGRP in vehicle or paclitaxel-treated rats. C: The total 
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The effects of paclitaxel on release of CGRP was examined after 
stimulation with a general depolarizing stimulus; 30 mM KCl. As in the 
previous series of studies, chronic administration with paclitaxel did not 
alter basal release of iCGRP (Figure 27A and B). Before stimulation, 
release of iCGRP from vehicle-injected animals was 0.80 ± 0.14 while that 
from paclitaxel-injected animals was 0.81 ± 0.07 % total content/9 min 
(Figure 28A). The amount of iCGRP release after stimulation of the slices 
with 30 mM KCl increased to 1.93 ± 0.23 and 2.10 ± 0.34 % total 
content/10 min in vehicle-injected and paclitaxel-injected animals 
respectively. The evoked release of iCGRP from sensory neurons was 
1.13 ± 0.31 and 1.29 ± 0.36 % total content/9 minutes (Figure 28B). The 
total amount of iCGRP in vehicle-injected animals was 642.66 ± 36.37 
while that in paclitaxel-injected animals was 565.95 ± 51.56 fmol/mg tissue 
(Figure 28C). These data indicate that paclitaxel does not alter the ability 
of sensory neurons to depolarize nor does it inhibit the mechanisms of 
neurotransmitter release. 
When the evoked release in both of the above described 
experiments were compared by the unpaired t-test, there were no 
statistically significant differences between the vehicle-injected animals 
and the paclitaxel-injected animals. Furthermore, the total content of 
iCGRP was not different between the 2 groups of animals. This suggests 
that paclitaxel at 1 mg/kg does not alter the transport of CGRP from the 
cell body to the central terminals of the primary afferent sensory neuron. 
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Furthermore, the dosing regimen of paclitaxel used does not alter the 
mechanism mediating CGRP release.  
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Figure 27. Chronic administration of 1 mg/kg paclitaxel does not alter 
iCGRP release stimulated by 30 mM KCl from rat spinal cord slices. Each 
column represents the mean ± SEM. The horizontal bar indicates the time 
when the tissues were exposed to 30 mM KCl. iCGRP release in each 3-
minute perfusion sample is expressed as percent of total peptide content 
per minute. A: iCGRP release in slices taken from vehicle-treated rats, B: 
iCGRP release in slices taken from paclitaxel-injected rats.  
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Figure 28. Potassium-evoked release of iCGRP is not altered by chronic 
administration of paclitaxel. Each column is the mean ± SEM. A: Basal 
release is the sum of the 3 collections prior to 30 mM KCl, whereas KCl-
stimulated release is the sum of the three collections in the presence of 30 
mM KCl B: Evoked release of iCGRP (KCl-stimulated release minus basal 
release presented in Figure A) in vehicle- or paclitaxel-treated rats, as 
indicated. C: The total content of iCGRP in the spinal cord slices from 
vehicle or paclitaxel injected animals. 
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It is known that paclitaxel does not readily cross the blood brain barrier 
(Lesser et al., 1995; Cavaletti et al., 2000; Fellner et al., 2002), which 
might explain the lack of systemic effects of the drug on CGRP release. 
To determine if higher doses of paclitaxel might alter release of CGRP 
from spinal cord slices, animals were injected with 2 mg/kg paclitaxel on 4 
consecutive days.  
The basal release of iCGRP in animals injected with 2mg/kg 
paclitaxel is not significantly different from that in vehicle-injected animals 
(Figure 29A and B). In vehicle-injected animals, iCGRP release increased 
from 1.13 ± 0.12 to 4.98 ± 0.57 % content/3 minutes after stimulation with 
capsaicin. The basal release in paclitaxel-treated animals was 0.94 ± 0.14 
% content/9 minutes while capsaicin-stimulated release was 3.28 ± 0.51 
% total content/9 minutes (Figure 30A). The evoked release of iCGRP was 
3.85 ± 0.62 and 2.34 ± 0.55 % total content/9 minutes in vehicle-injected 
and paclitaxel-injected animals respectively (Figure 30B). Furthermore, 2 
mg/kg paclitaxel did not alter the total content of iCGRP in the spinal cord: 
the total amount of iCGRP in vehicle-injected animals was 503.7 ± 44.82 
and that in paclitaxel-injected animals was 497.7 ± 46.31 fmol/mg 
respectively (Figure 30C).  
In summary, paclitaxel at the doses administered did not alter the 
release of iCGRP from sensory nerve terminals in spinal cord slices 
irrespective of the stimulus used. Since these doses do alter release in the 
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periphery, the data suggest that paclitaxel alters the peripheral nerve 
endings of sensory neurons while the central terminals remain unaffected.  
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Figure 29. Chronic administration of 2 mg/kg paclitaxel does not alter 
capsaicin-evoked iCGRP release from rat spinal cord slices. Each column 
represents the mean ± SEM. The horizontal bar indicates the time when 
the tissues were exposed to capsaicin. iCGRP release in each 3-minute 
perfusion sample is expressed as percent of total peptide content per 
minute. A: iCGRP release in slices taken from vehicle-treated rats.  
B: iCGRP release in slices taken from paclitaxel-injected rats. 
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Figure 30. Release of iCGRP induced by capsaicin is not statistically 
significant between slices from vehicle-injected or 2 mg/kg paclitaxel-
injected animals. Each column represents the mean ± SEM. A: Basal 
release is the sum of the 3 collections prior to capsaicin, whereas 
capsaicin-stimulated release is the sum of the three collections in the 
presence of capsaicin B: Evoked release of iCGRP in vehicle or paclitaxel-
treated rats. C: The total content of iCGRP in the spinal cord slices from 
vehicle or paclitaxel injected animals. 
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Exposure of sensory neurons in culture to 300 nM or 1 µM paclitaxel 
decreases capsaicin-evoked iCGRP release 
Since paclitaxel appears to alter the release of CGRP from the 
peripheral terminals of sensory neurons, this phenomenon was further 
examined in isolated sensory neurons so that the mechanisms mediating 
this change in function can be further examined.  
Dorsal root ganglia were harvested from male Sprague Dawley 
rats, were dissociated, maintained in culture and exposed to various 
concentrations of paclitaxel for 5 days. As can be seen in Table 3, basal 
release of iCGRP and total content of iCGRP was not altered by any 
concentration of paclitaxel that were tested. In contrast paclitaxel did alter 
the capsaicin-evoked release of iCGRP from sensory neurons in a 
concentration dependent manner (Figure 31A). The amount of iCGRP 
released from untreated neurons was 19.91 ± 1.71 % content/10 minutes. 
Exposure of sensory neurons to 10 or 30 nM paclitaxel significantly 
increased capsaicin-evoked release of iCGRP to 25.63 ± 0.9 and 24.06 ± 
0.8 % content/10 min respectively. In contrast, exposure to 100 nM, 300 
nM or 1 µM paclitaxel significantly decreased capsaicin-evoked release to 
13.32 ±1.16, 8.16 ± 0.79 and 4.82 ± 0.85 % content/10 minutes 
respectively. The altered release of iCGRP was not secondary to an 
altered content of the peptide (see Table 2 and Figure 31B). Some 
cultures were also exposed to the vehicle for paclitaxel (0.01% MPL) for 5 
days to determine if the vehicle itself altered basal or capsaicin-evoked 
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release of iCGRP. Capsaicin-stimulated release from vehicle treated 
neurons was 20.64 ± 1.43 % total content/10 minutes. These values were 
not significantly different from those in untreated neurons.  
It is possible that paclitaxel decreases the ability of capsaicin to 
stimulate TRPV1. Therefore, I examined if release of iCGRP by 100 nM 
capsaicin was altered by 1 µM paclitaxel. In untreated neurons release of 
iCGRP increased from a basal value of 0.92 ± 0.12 to 39.90 ± 1.21 % total 
content/10 minutes after stimulation by 100 nM capsaicin. In neurons 
exposed to 300 nM or 1 µM paclitaxel for 5 days the release of iCGRP 
increased from 1.59 ± 0.35 to 22.53 ± 1.05 % total content/10 minutes and 
from 1.62 ± 0.37 to 18.51 ± 1.66 % total content/10 minutes respectively 
(Figure 32A). Overall, iCGRP release evoked by 100 nM capsaicin in 
paclitaxel-treated neurons was still significantly lower than release from 
untreated neurons.  
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Treatment Basal release (% content/10 min) 
Total Content 
(fmol/well) 
Control 1.16 ± 0.2 2030.06 ± 148.37 
Vehicle (0.01% 
MPL) 0.99 ± 0.21 2096.23 ± 232.74 
10 nM 0.93 ± 0.05 1596 ± 136.80 
30 nM 1.05 ± 0.07 1934 ± 173.90 
100 nM 1.49 ± 0.16 1439 ± 112.90 
300 nM 1.65 ± 0.19 1899.37 ± 156.67 
1 µM 1.60 ± 0.32 1935.35 ± 350.01 
 
Table 3. Basal release and total content of iCGRP from untreated, vehicle 









Figure 31. Paclitaxel alters release of iCGRP from isolated sensory 
neurons in response to 30 nM capsaicin. Columns are the mean ± SEM of 
iCGRP released as % total content/10 min. A: Open columns represent 
basal release of iCGRP during a 10 minute incubation with buffer. Solid 
columns represent release of iCGRP stimulated by 10 minute incubation 
with 30 nM capsaicin. B: Total content of iCGRP in sensory neurons. 
Asterisks indicate statistically significant differences in capsaicin-evoked 
iCGRP release between paclitaxel-treated and untreated neurons by one-










Figure 32. Paclitaxel (300 nM or 1 µM for 5 days) decreases iCGRP 
release from isolated sensory neurons evoked by 100 nM capsaicin. 
Columns are the mean ± SEM of iCGRP released as % total content/10 
min. A: Open columns represent basal release of iCGRP during a 10 
minute incubation with buffer. Solid columns represent release of iCGRP 
stimulated by 100 nM capsaicin. B: Total content of iCGRP in sensory 
neurons treated with paclitaxel at the concentrations indicated. An asterisk 
indicates statistical significance between paclitaxel-treated and untreated 
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To determine if paclitaxel alters the viability of sensory neurons, 
neuronal cultures that were exposed to paclitaxel were stained with PI and 
Annexin V. PI is a DNA intercalating agent that is impermeant in living 
cells because of it size but is able to penetrate the membrane of dead 
cells. After staining with PI, it is possible to discriminate between live and 
dead cells, but not between apoptotic and necrotic cell death. Therefore 
simultaneous labeling with annexin V was performed. Annexin V has a 
high affinity for phosphotidylserine (PS), which is located in the inner 
(cytoplasmic) leaflet of the cell membrane. Following induction of 
apoptosis, PS is translocated to the outer (cell surface) leaflet of the cell 
membrane, where it is now easily accessible to annexin V in the staining 
solution. Cells that are in the initial stages of apoptosis display a green 
colored ring around the cells, while dead cells show more diffused 
staining.  
 As shown in Figure 33A and B, the number of untreated sensory 
neurons that stained positive for annexin V or PI was 8.3 ± 1.9 % and 8.0 
± 2.3 % of the total number of neurons counted. When neurons were 
exposed to 300 nM paclitaxel for 5 days, the number of annexin V positive 
neurons was 10.7 ± 2.3 % while those that stained positive for PI was 10.3 
± 3 % of total number of neurons counted. Paclitaxel at 1 µM for 5 days 
caused 4 ± 2 % and 9 ± 3 % of the total number of neurons to stain 
positive for annexin V and PI respectively. When neurons were exposed to 
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300 µM H2O2 as the positive control, the annexin V and PI positive cells 
were 63.7 ± 14% and 69.3 ± 18.6 % respectively.  
From these data it can be seen that paclitaxel at 300 nM or 1 µM for 5 
days, did not decrease the survival of sensory neurons, thus the decrease 
in release of CGRP is not likely the result of cell death. 




Figure 33. Paclitaxel at 300 nM or 1 µM for 5 days does not decrease the 
survival of sensory neurons in culture. Each column is the mean ± SEM. 
The number of annexin V positive (A) or PI positive (B) neurons were 
counted in a minimum of 5 fields from 3 different harvests and was 
normalized to the total number of neurons in the field. An asterisk 
indicates significant difference from untreated controls by one way - 
ANOVA and Bonferroni’s post test, p < 0.05. 
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Exposure of sensory neurons in culture to 300 or 1 µM paclitaxel does not 
decrease KCl evoked release of iCGRP 
A possible explanation for the diminished release of capsaicin-
evoked release of CGRP by higher concentrations paclitaxel is that the 
microtubule-stabilizing drug directly alters the release mechanism for 
CGRP. Therefore a general depolarizing stimulus, namely 30 mM KCl was 
used to evoke release of CGRP from sensory neurons that were exposed 
to paclitaxel to determine if the anticancer drug alters release by a 
depolarizing stimulus. 
Figure 34A shows that exposing untreated or vehicle-treated 
sensory neurons to 30 mM KCl increased iCGRP release from a basal 
value of 1.32 ± 0.16 to 14.19 ± 1.35 and from 1.44 ± 0.21 to 15.02 ± 1.07 
% content/10 minutes respectively. Basal release in neurons exposed to 
300 nM or 1 µM paclitaxel was 1.37 ± 0.12 and 1.69 ± 0.16 % content/ 10 
minutes respectively. After incubation with 30 mM KCl for 10 minutes, 
iCGRP release increased to 16.4 ± 2.64 and 16.58 ± 1.44 % content/ 10 
minutes in neurons exposed to either 300 nM or 1000 nM paclitaxel 
respectively. The stimulated release in paclitaxel- treated neurons (300 
nM or 1 µM) was not significantly different from untreated controls. 
Additionally, the total content of iCGRP was not different across the 
treatment groups (Figure 34B). Content of the peptide was 2052 ± 144.7, 
1955 ± 206.4, 1853 ± 234.4 and 1822 ± 211.5 fmol/well in untreated 
neurons, vehicle treated, and 300 nM or 1 µM paclitaxel-treated neurons. 
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These data clearly demonstrate that paclitaxel does not alter potassium-
evoked release of iCGRP from sensory neurons suggesting that the drug 
does not affect the exocytosis process. 
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Figure 34. Paclitaxel (300 nM or 1 µM for 5 days) does not alter iCGRP 
release evoked by high extracellular potassium from isolated sensory 
neurons. Columns are the mean ± SEM of iCGRP released as % total 
content/10 min. A: Open columns represent basal release of iCGRP 
during a 10 minute incubation with buffer. Solid columns represent release 
of iCGRP stimulated by 30 mM KCl for 10 minutes. B: Total content of 
iCGRP in sensory neurons.  
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Expression of TRPV1 after exposure to sensory neurons to paclitaxel 
One mechanism that could account for the ability of paclitaxel to 
attenuate capsaicin-evoked release of iCGRP could be a change in the 
TRPV1 receptor. Consequently, I examined the expression of TRPV1 by 
western blot and real-time PCR to quantify mRNA. 
Representative blots demonstrating expression of TRPV1 after 
exposure to 300 nM or 1 µM paclitaxel at different times are shown in 
Figure 35A. The summary data from these blots are shown in Figure 36A. 
The immunoreactivity for TRPV1 after exposure to 300 nM paclitaxel for 1 
day was 67.42 ± 18.52 % of control and this decrease was not significantly 
different from that in untreated control. However, the decrease in 
immunoreactivity to 36 ± 12.12 %, 30.61 ± 5.79 % and 5.56 ± 3.6 % of 
control after 1, 2, 3 and 5 days respectively was significantly lower than 
that in untreated neurons.  
Exposure to 1 µM paclitaxel for 1 day also did not significantly 
decrease immunoreactivity of TRPV1 (70. 01 ± 24.87 % of control). 
Exposure for 2, 3 and 5 days decreased immunoreactivity to 38 ± 7.02 %, 
21.55 ± 5.7 % and 2.18 ± 1.70 % of control respectively (Figure 36B).  
As a positive control I also examined immunoreactivity of a 
syntaxin, a membrane-associated SNARE protein that is involved in the 
exocytosis of neurotransmitters. Interestingly, as shown in Figure 35B and 
36C, 300 nM or 1 µM paclitaxel for 5 days did not alter the expression of 
syntaxin (113.5 ± 2.05 % and 122.9 ± 3.47 % of control respectively).  
	   	   	   	   	   123 
These data clearly suggest that paclitaxel decreases the 
expression of the protein for TRPV1 in a manner that is dependent on the 
concentration and the period of exposure. Since exposure to 300 nM or 1 
µM paclitaxel for 5 days did not alter expression of syntaxin, I did not 
examine syntaxin expression at earlier time points.  
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Figure 35. Exposure of sensory neurons to 300 nM or 1 µM paclitaxel 
decreases expression of TRPV1 protein but not of syntaxin. A: 
Representative blots demonstrating immunoreactivity for TRPV1 after 
exposure to paclitaxel at the concentrations and times indicated B: 
Representative blots demonstrating immunoreactivity for syntaxin.  




Figure 36. Densitometry of immunoreactive TRPV1 and syntaxin bands. 
A: Densitometric analysis of signal for TRPV1 after exposure to 300 nM 
paclitaxel for the duration indicated. Each column is the mean ± SEM of 
the ratio of TRPV1/actin normalized to that of untreated control. B: 
Densitometric analysis of signal for TRPV1 after exposure to 1 µM 
paclitaxel for the duration indicated. Each column is the mean ± SEM of 
the ratio of syntaxin/actin normalized to that of untreated control. C: 
Densitometric analysis of signal for syntaxin after exposure to 300 nM or 1 
µM paclitaxel for 5 days. An asterisk indicates statistical significance 
determined by one-way ANOVA with Bonferroni’s post test to determine 
differences in TRPV1 immunoreactivity between paclitaxel-treated and 
untreated neurons (p < 0.05). 
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Exposure of isolated sensory neurons to 300 nM or 1 µM paclitaxel 
decreases mRNA of TRPV1 and Nav1.9 
  The decrease in TRPV1 immunoreactivity could result from 
increased degradation of the protein, or to decreased transcription 
resulting in decreased translation or both. To ascertain whether paclitaxel 
can decrease TRPV1 message, real-time PCR experiments were 
performed and relative quantification was achieved by the comparative CT 
method, also known as the 2-∆∆CT method. 
Exposing sensory neurons to vehicle (0.01% MPL) for 5 days did 
not alter the mRNA for TRPV1 in the cultures (Figure 37A). Exposure to 
300 nM paclitaxel for 1, 2 or 3 days significantly decreased mRNA to 
57.52 ± 7.7 %, 25.96 ± 3.32 %, 13.45 ± 2.18 % of control respectively 
(Figure 37B). The decrease in mRNA by 1 µM paclitaxel was 53.13 ± 6.89 
%, 18.83 ± 1.6 %, 11.41 ± 2.37 % after exposure for 1, 2 and 3 days 
respectively (Figure 37C).  
I also examined TRPV1 mRNA expression in sensory neurons 
exposed to 10 nM, 30 nM and 100 nM paclitaxel for 5 days. In neurons 
exposed to 10 nM of the drug the mRNA for TRPV1 was not different from 
untreated control (93.18 ± 8.53 % of control, Figure 37D). However, 
exposure to 30 nM and 100 nM for 5 days significantly decreased TRPV1 
mRNA to 66.23 ± 5.28 and 36.6 ± 4.07 % of control respectively (Figure 
37D).  
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I next determined if paclitaxel alters the expression of mRNA for the 
voltage-gated sodium channel Nav1.9 as a control. Exposure of sensory 
neuron cultures to 0.01% MPL for 5 days did not alter the mRNA for 
Nav1.9 - 77.23 ± 5.6 % of control (Figure 38A). Exposure of sensory 
neurons to 300 nM paclitaxel for 1, 2 or 3 days significantly decreased 
Nav1.9 mRNA to 57.52 ± 7.7 %, 25.96 ± 3.32 %, 13.45 ± 2.18 % of control 
respectively. The Nav1.9 mRNA after 1 µM paclitaxel for 1, 2 and 3 days 
decreased to 37.89 ± 6.67 %, 13.58 ± 3.38 %, 9.83 ± 1.28 % of control 
respectively (Figure 38B and C). Exposure to 10 nM of the anti-cancer 
drug for 5 days did not alter expression of Nav1.9 mRNA (95.04 ± 3.34 % 
of control, Figure 38D). However exposure to 30 nM, 100 nM, 300 nM or 1 
µM paclitaxel for 5 days significantly decreased Nav1.9 mRNA to 58.19 ± 
3.29, 28.63 ± 2.99, 11.73 ± 1.94, and 4.73 ± 0.72 % of control respectively 
(Figure 38B, C and D).  
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Figure 37. Paclitaxel alters TRPV1 mRNA in isolated sensory neurons. 
Total RNA was extracted from untreated, vehicle (0.01% MPL) or 
paclitaxel-treated neurons at the concentrations and durations indicated 
and reverse transcribed to cDNA. Relative quantification was achieved by 
the 2-ΔΔCT method. Each column is the mean ± SEM of the fold- change in 
mRNA expression relative to untreated control. A: Fold change in TRPV1 
mRNA in vehicle treated or untreated neurons. B: Fold change in TRPV1 
mRNA in neurons exposed to 300 nM for the times indicated. C: Fold 
change in TRPV1 mRNA in neurons exposed to 1 µM paclitaxel for the 
times indicated. D: Fold change in TRPV1 exposed to 10 nM, 30 nM and 
100 nM paclitaxel for 5 days. Asterisks indicate statistically significant 
differences between paclitaxel-treated neurons and untreated controls 
determined by one-way ANOVA and Bonferroni’s post test, p < 0.05. 
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Figure 38. Paclitaxel alters Nav1.9 mRNA in isolated sensory neurons. 
Total RNA was extracted from untreated, vehicle (0.01% MPL) or 
paclitaxel-treated neurons at the concentrations and durations indicated 
and reverse transcribed to cDNA. Relative quantification was achieved by 
the 2-ΔΔCT method. Each column is the mean ± SEM of the fold- change in 
mRNA expression relative to untreated control. A: Fold change in Nav1.9 
mRNA in vehicle treated or untreated neurons. B: Fold change in Nav1.9 
mRNA in neurons exposed to 300 nM for the times indicated. C: Fold 
change in Nav1.9 mRNA in neurons exposed to 1 µM paclitaxel for the 
times indicated. D: Fold change in Nav1.9 exposed to 10 nM, 30 nM and 
100 nM paclitaxel for 5 days. Asterisks indicate statistically significant 
differences between paclitaxel-treated neurons and untreated controls 
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Chronic administration of 2 mg/kg or 4 mg/kg but not 1 mg/kg paclitaxel 
decreases mRNA for TRPV1 
Because paclitaxel altered the expression of TRPV1 in vitro, 
experiments were performed to determine if expression was altered in 
vivo. As previously described male Sprague Dawley rats were injected 
with either 1 mg/kg, 2 mg/kg or 4 mg/kg paclitaxel every other day for a 
total of 4 doses. Two weeks after the 1st injection, the L4, L5, and L6 
lumbar DRGs were removed and total RNA was extracted for real time 
PCR experiments. The lumbar ganglia were chosen because these DRGs 
innervate the paw where the measurements of blood flow were made. As 
shown in Figure 39, 1 mg/kg paclitaxel did not alter TRPV1 mRNA. When 
expressed as percent of control, TRPV1 mRNA in paclitaxel-injected 
animals was 100.4 ± 7.9 %. When the dose of paclitaxel was increased to 
2 mg/kg or 4 mg/kg, mRNA levels were decreased to 61.09 ± 2.56 % and 
54.72 ± 7.24 % of control respectively.  




Figure 39. Chronic administration of 2mg/kg or 4 mg/kg but not 1 mg/kg 
paclitaxel in rats decreases TRPV1 mRNA in the dorsal horn of the spinal 
cord. Columns are the mean ± SEM of fold changes in TRPV1 relative to 
vehicle-injected control. An asterisk indicates statistically significant 
differences in TRPV1 mRNA from paclitaxel-injected or vehicle-injected 
animals by one-way ANOVA and Bonferroni’s post test, p < 0.05. 
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Paclitaxel decreases the length of neurites in isolated sensory neurons 
It is possible that distal degeneration of the peripheral process of 
DRGs contributes to the decreased vasodilatation after activation of 
sensory neurons. Indeed axonal degeneration has been observed in sural 
nerve biopsies from patients and it has already been demonstrated that 
paclitaxel alters the length of neurites in sensory neurons in culture (Yang 
et al., 2009). To determine if paclitaxel causes neurite degeneration, I 
established an experimental model to examine length of neurites in 
isolated sensory neurons following exposure to the anti-cancer drug. As 
outlined in the methods section isolated sensory neurons were shot with 
gold particles that were previously coated with the cDNA for EGFP. The 
process of shooting gold particles at high velocity and pressure into 
sensory neurons did not affect the growth or development of neuronal 
processes. Neurons that were exposed to vehicle (0.01 % MPL for 5 days) 
maintain their morphology and integrity up to day 12 in culture. (Figure 
40). 
Images of untreated sensory neurons were acquired on day 7 in 
culture. Some cultures were exposed to 10 nM, 100 nM or 300 nM 
paclitaxel immediately after acquisition of images. Additional images of 
neurons were obtained on day 9 (2 days after addition of paclitaxel), and 
finally on day 12 (after 5 days of exposure to paclitaxel). Representative 
images of neurons exposed to 300 nM paclitaxel show that the length of 
neurites decreased over time following addition of the drug (Figure 41). 




Figure 40. Sensory neurons exposed to vehicle (0.01% MPL) for 5 days 
do not undergo changes in neurite length. A: Sensory neuron expressing 
EGFP on day 7 in culture, 0.01% MPL was added immediately after image 
acquisition. B: The same neuron on day 9 (2 days after addition of 
vehicle). C: Neuron on day 12 (5 days after addition of vehicle). 






Figure 41. Paclitaxel at 300 nM decreases the length of neurites in 
isolated sensory neurons. A: Sensory neuron expressing EGFP on day 7 
in culture. Paclitaxel was added immediately after image acquisition. B: 
The same neuron on day 9 (2 days after addition of paclitaxel). C: Neuron 
on day 12 (5 day after addition of paclitaxel). 
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 The neurite outgrowth software was used for the calculation of total 
outgrowth - the cumulative length of all neurites protruding from a single 
cell body. The outgrowth after exposure to vehicle or paclitaxel (on day 9 
and day 12) is normalized to that before addition of vehicle or paclitaxel 
(day 7) and is expressed as % of total outgrowth.  
As illustrated in Figure 42A, the total outgrowth on day 9 and day 
12 after exposure to 0.01% MPL is 107.6 ± 8 and 95.3 ± 9.24 % of the 
total length respectively, which is not significantly different from the length 
on day 7. This suggests that the vehicle did not alter the length of neurites. 
When neurons were exposed to 10 nM paclitaxel, the length of neurites on 
day 9 was 117.1 ± 16.12 % of total length, and on day 12 was 104.9 ± 
17.74 % of total length (Figure 42B). Since these values were not 
significantly different from length on day 7, it can be concluded that 10 nM 
paclitaxel does not alter the length of neurites.  
The length of neurites after exposure to 100 nM paclitaxel 
decreased to 77.1 ± 5.5% and 73.7 ± 6.4 % of the total length on day 9 
and day 12 respectively. (Figure 42C). In neurons exposed to 300 nM 
paclitaxel, the length of neurites decreased to 53.7 ± 4.8 % on day 9 and 
to 32.5 ± 4.4% on day 12 (Figure 42D). The length of neurites after 
exposure to 100 or 300 nM paclitaxel was significantly different from total 
length. Overall, 100 and 300 nM but not 10 nM paclitaxel decreased the 
length of neurites. 
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Figure 42. Exposure of sensory neurons in culture to 100 or 300 nM but 
not 10 nM paclitaxel decreases the length of neurites. The cDNA for 
EGFP was introduced into sensory neurons by a gene gun on day 2 in 
culture. Neurons stably expressed EGFP on day 7 in culture. Columns are 
mean ± SEM. The length of neurites was reported an % change relative to 
that on day 7 in neurons treated for 5 days with vehicle (0.01% MPL) (A), 
10 nM paclitaxel (B), 100 nM paclitaxel (C) or 300 nM paclitaxel (D). An 
asterisk indicates statistically significant differences in neurite length 
relative to day 7. Significance was tested by one-way ANOVA and 
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DISCUSSION 
Paclitaxel-induced peripheral neuropathy is largely a sensory 
neuropathy since its major actions are directly or indirectly on sensory 
neurons. The symptoms associated with the neuropathy are experienced 
in the hands and the feet, and occur at doses greater than 200 mg/m2 
(Lipton et al., 1989; Mielke et al., 2005), and no treatments are currently 
available to prevent or reverse the neurotoxicity because the mechanisms 
mediating the toxicity are still not known. Therefore this study was 
performed to examine the mechanisms mediating the paclitaxel-induced 
change in function of sensory neurons. The experiments conducted in this 
study provide evidence that paclitaxel alters the function of peripheral 
endings of small diameter sensory neurons in vivo which was 
demonstrated by a reduction in the ability of the peptidergic sensory 
neurons to increase peripheral blood flow. However, the microtubule-
stabilizing drug does not alter the release of CGRP from the central 
terminals of the peptidergic neurons. Experiments performed in isolated 
sensory neurons demonstrated that paclitaxel directly alters the release of 
the neuropeptide from sensory neurons, and alters the expression of the 
capsaicin receptor TRPV1 and the voltage-gated sodium channel Nav1.9. 
Lastly, paclitaxel causes degeneration of neurites in isolated sensory 
neurons.  
A number of investigators have examined the effects of various 
dosing regimens of paclitaxel in animal models on different endpoints 
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including sensory nerve conduction (Apfel et al., 1991; Cavaletti et al., 
1995; Cavaletti et al., 1997; Cliffer et al., 1998; Authier et al., 2000; 
Persohn et al., 2005; Matsumoto et al., 2006; Jamieson et al., 2007; 
Nishida et al., 2008), response to thermal and mechanical stimuli (Apfel et 
al., 1991; Cavaletti et al., 1995; Cavaletti et al., 1997; Campana et al., 
1998; Authier et al., 2000; Dina et al., 2001; Polomano et al., 2001; 
Persohn et al., 2005; Matsumoto et al., 2006; Peters et al., 2007; Nishida 
et al., 2008), and morphological changes in sensory nerves (Cavaletti et 
al., 1995; Schmidt et al., 1995; Cavaletti et al., 1997; Campana et al., 
1998; Authier et al., 2000; Polomano et al., 2001; Persohn et al., 2005). In 
most of these studies, the effects of paclitaxel on the above mentioned 
endpoints are dependent on the total amount of paclitaxel administered. 
For example, rats administered greater than 16 mg/kg paclitaxel showed 
decreased sensory nerve conduction velocity, a decrease in sensitivity to 
thermal stimuli, and altered morphology of sensory nerves (Sahenk et al., 
1994). On the other hand, when lower doses of paclitaxel (10 mg/kg or 
less) are administered, the drug produces an increased sensitivity to 
thermal and mechanical stimuli analogous to models of neuropathic pain 
syndromes. These dose dependent changes in sensitivity of sensory 
neurons have been observed in patients as well. Furthermore, the 
hypernociception observed in animal models was not accompanied by 
visible signs of nerve damage (Dina et al., 2001; Polomano et al., 2001; 
Weng et al., 2005).  
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Although the animal models do exhibit symptoms experienced by 
patients (altered sensitivity to thermal and mechanical stimuli and altered 
sensory nerve conduction), a limitation of most of these models including 
the one used in this study is that the effects of paclitaxel are examined in 
the absence of tumors. Therefore the contribution of cells of the immune 
system to changes in sensory neuron function cannot be examined in 
these animal models. Another limitation is that the severity of the 
symptoms of peripheral neuropathy in patients increases when other 
anticancer drugs e.g. cisplatin is administered in combination with 
paclitaxel, and when there are preexisting conditions including diabetes, 
alcoholism or other metabolic disorders (vitamin deficiencies); animal 
models for the examination of peripheral neuropathy do not account for 
these variables.  
 
Effects of paclitaxel on sensory neuron function in vivo 
The injection regimen in the experiments conducted in this study (1 
mg/kg every other day for a total of 4 doses) was chosen because the 
dose is low enough that produces a change in sensory neuron function in 
the absence of any overt signs of toxicity (Polomano et al., 2001). My work 
also differs from others in the choice of vehicle used. Cremophor EL 
(CrEL), which is a polyethoxylated castor oil and ethanol in a ratio of 1:1 is 
the vehicle currently used when paclitaxel is administered to patients and 
by many investigators injecting the drug in animals. However CrEL itself is 
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associated with hypersensitivity reactions and other toxicities (Gelderblom 
et al., 2001; Ten Tije et al., 2003). Therefore, to eliminate effects produced 
by this vehicle, I used 10% DMSO as the vehicle. Moreover, Polomano et 
al., showed that 10% DMSO does not produce a change in basal 
nociceptive behavior or any signs of toxicity (Polomano et al., 2001). 
 In a number of studies using animal models the paclitaxel is given 
intravenously because this route is most frequently used in the clinic. In 
contrast, I chose the i.p route of administration because it enables 
injections of larger volumes of the drug and it eliminates the need for 
canulation of blood vessels for the administration of the drug. Secondly, 
Soma et al., showed that when injected intraperitoneally, paclitaxel 
persists in extra-peritoneal tissues longer than when injected intravenously 
(Soma et al., 2009) and for this reason intraperitoneal administration of 
paclitaxel has been proposed to be more beneficial in the treatment of 
ovarian cancers (Markman et al., 1994; Francis et al., 1995; Ishigami et 
al., 2009; Ishigami et al., 2010).  
 
Measurement of cutaneous vasodilatation to examine release of CGRP 
from peripheral endings of senory neurons in vivo 
The various symptoms associated with paclitaxel-induced 
peripheral neuropathy could result from an altered function of both 
myelinated and unmyelinated sensory fibers. A loss of vibration sense, 
loss of propioception and loss of deep tendon reflexes suggest a 
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dysfunction of the large myelinated fibers (Aβ). The decrease in thermal 
nociceptive threshold, burning pain, and paraesthesia experienced by 
patients with paclitaxel-induced peripheral neuropathy parallel 
observations made in patients with other small fiber neuropathies (Tavee 
and Zhou, 2009), suggesting that paclitaxel causes abnormalities in the 
function of the small diameter fibers (Aδ and C). Furthermore, a sural 
nerve biopsy from a patient receiving paclitaxel and one animal study 
showed degeneration of myelinated as well as unmyelinated fibers after 
administration of multiple injections of paclitaxel (Sahenk et al., 1994; 
Authier et al., 2000).  
In contrast to the above observations of decreased nociceptive 
threshold after paclitaxel administration, Dougherty et al., observed that 
patients undergoing chemotherapy with paclitaxel demonstrated increased 
touch thresholds suggesting a loss of Aβ fiber function, while their ability to 
detect thermal stimuli were the same as in control subjects, suggesting 
that the neurons that convey thermal stimuli (Aδ and C) are unaffected by 
the drug treatment (Dougherty et al., 2004). In animal studies using an 
intravenous dosing regimen of paclitaxel (1 mg/kg per day for 10 days), no 
changes were observed in the thermal threshold or the conduction velocity 
of C fibers suggesting that paclitaxel did not alter excitability of small 
diameter sensory fibers (Dina et al., 2001). Whether the function of the 
small diameter fibers is altered by paclitaxel is still uncertain because 
studies examining nerve conduction and behavior do not reflect function of 
	   	   	   	   	   142 
the small diameter nerve fibers. Electrodiagnostic tests are able to 
distinguish between the large diameter neuropathies while small fiber 
function often appears normal in these studies (Mendell and Sahenk, 
2003; Tavee and Zhou, 2009). Therefore, the studies conducted in this 
thesis were designed to specifically examine if paclitaxel alters release of 
CGRP from the peripheral and central terminals of the small sensory 
fibers in vivo and in vitro. Release of CGRP from the peripheral endings of 
sensory neurons was measured by examining vasodilatation after 
activation of the peripheral terminals of sensory neurons. It is well 
established that a subset of small diameter sensory neurons release 
CGRP from the peripheral endings in response to a stimulus (Franco-
Cereceda et al., 1987; Rydh et al., 1992; Kilo et al., 1997; Averbeck and 
Reeh, 2001) and this release results in an increase in blood flow in 
peripheral targets (Brain et al., 1986; Merhi et al., 1998; Grant et al., 
2002). Vasodilatation induced by sensory neuron activation is an 
important component of neurogenic inflammation and is produced at the 
site of injury after activation of sensory neurons by thermal, mechanical or 
thermal stimuli (Koltzenburg and McMahon, 1986; Holzer, 1998). Thus, as 
an indirect measure of CGRP release, cutaneous vasodilatation using 
laser Doppler flowmetry was examined. To implement the method, 
experiments were performed to characterize vasodilatation after activation 
of sensory neurons. In the initial experiments, injection of capsaicin 
produced only a modest increase in blood flow compared to that observed 
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by others (Hughes and Brain, 1991; Lin et al., 1999). Several variables 
could account for the weak detection of the response. The volume of 
tissue sampled by the laser probe is approximately 0.6 mm3. Therefore 
the placement of the probe relative to the site of injection is important for 
detection of changes in signal. Accordingly, injecting drugs 1 mm away 
from the site of the probe enables detection of signal. Initial experiments 
were performed by injecting 10 µM capsaicin into the subcutaneous layer 
of the skin. Since the laser penetrates to a depth of approximately 600 µm, 
the laser probe will not detect blood flow increases induced by injection of 
capsaicin into deeper layers of the skin; only those changes occurring in 
the superficial layers (dermis) can be detected. Therefore, in subsequent 
experiments the needle was inserted at a 15-degree angle to ensure 
intradermal injection of drug. The volume of injection can also influence 
detection of blood flow by the laser probe. Larger volumes (≥ 10 µl) could 
interfere with the path of the laser; therefore I chose to use 1 µl in 
subsequent experiments. Injecting 1 µl capsaicin in the superficial layer of 
the skin allowed detection of almost 200% increase in blood flow in 
response to injection of 10 µM capsaicin, thus this protocol was used in all 
future experiments of cutaneous vasodilatation.  
For experiments to examine vasodilatation in response to electrical 
stimulation, a modification of the protocol described by Koltzenburg et al., 
was used (Koltzenburg et al., 1990). The sciatic nerve was axotomized 
before stimulation of the sciatic nerve in order to eliminate dorsal root 
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reflexes that arise in the spinal cord. Although the data was not shown, in 
initial experiments, axotomy produced an increase in basal blood flow 
possibly resulting from injury induced firing of action potentials. 
Consequently, application of 1% lidocaine to the area distal to the site of 
cutting the sciatic nerve was used to prevent action potential conduction. 
This treatment eliminated the increase in basal blood flow following 
axotomy (data not shown). The sciatic nerve was then stimulated at 5 mA 
at 10 Hz for 30s because this stimulus activates the high threshold Aδ and 
C fibers along with the low threshold Aβ to produce maximum 
vasodilatation (Koltzenburg et al., 1990). The vasodilatation produced by 
electrical stimulation of the sciatic nerve is similar to that observed by 
Escott et al., after stimulation of the saphenous nerve (Escott and Brain, 
1993). 
To determine if vasodilatation caused by activation of sensory 
neurons is mediated by CGRP, I examined if the CGRP receptor 
antagonist (CGRP8-37) would block the increase in blood flow induced by 
electrical stimulation of the sciatic nerve or by intradermal injection of 
capsaicin. CGRP8-37 displaces the specific binding of human αCGRP in rat 
liver membranes and inhibits the production of cAMP by human CGRP in 
a dose dependent manner (Chiba et al., 1989). Furthermore, Dennis et al., 
demonstrated that CGRP8-37 is a more potent antagonist in the right 
guinea pig atrium and the guinea pig ileum but a weaker antagonist in the 
rat vas deferens suggesting that CGRP8-37 discriminates between different 
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types of the CGRP receptor (Dennis et al., 1990). This antagonist also 
inhibits the increase in blood flow induced by CGRP (Hughes and Brain, 
1991). 
To examine the effects of CGRP8-37 I chose to use 30 µM in part 
because this concentration does not alter basal blood flow (Hughes and 
Brain, 1991). Furthermore, this concentration inhibited the increase in 
blood flow induced by 100 µM capsaicin injected intradermally in the rat 
hind paw (Hughes and Brain, 1991). Using 30 µM CGRP8-37 in my 
preparation completely inhibited increase in blood flow induced by 
capsaicin or by electrical stimulation confirming previous work that the 
activation of sensory neurons induces vasodilatation in a CGRP 
dependent manner, (Hughes and Brain, 1991; Escott et al., 1995).  
One significant finding of my work is that paclitaxel significantly 
decreases vasodilatation induced by activation of sensory neurons. The 
decreased vasodilatation cannot be attributed to a decrease in expression 
of TRPV1 in the skin as has been observed in skin biopsies of patients 
with diabetic neuropathy (Facer et al., 2007), because electrical 
stimulation mediated vasodilatation was similarly attenuated by paclitaxel. 
Many other factors could contribute to decreased vasodilatation induced 
by paclitaxel. It is possible that the drug alters the function of blood 
vessels to cause a decrease in sensory neuron mediated vasodilatation 
because the paclitaxel has been shown to alter the contractility of aortic 
smooth muscle cells (Sauro et al., 1995), block proliferation and motility of 
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endothelial cells in vitro (Belotti et al., 1996) and prevent formation of new 
blood vessels (Wang et al., 2003b; Kirchmair et al., 2007; Lainer-Carr and 
Brahn, 2007). It is also possible that paclitaxel decreases the expression 
or function of the CGRP receptor on vascular smooth muscle cells. 
Therefore, to determine if the decreased vasodilatation induced by 
paclitaxel is secondary to a post-synaptic action, the effects of paclitaxel 
on vasodilatation induced by intradermal injection of CGRP and the 
muscarinic receptor agonist, methacholine (Kimura et al., 2007) was 
examined. Chronic administration of paclitaxel did not alter the increase in 
blood flow induced by either methacholine or CGRP. These data suggest 
that paclitaxel does not decrease the expression of the CGRP receptor, or 
interfere with vascular smooth muscle relaxation and support the notion 
that paclitaxel decreases cutaneous vasodilatation by inhibiting release of 
CGRP from sensory nerve endings.  
It is possible that the decreased release of CGRP from peripheral 
endings in paclitaxel-injected animals is secondary to decreased axonal 
transport of CGRP containing vesicles. There is morphological evidence 
that microtubules associate with synaptic vesicles and functional evidence 
that microtubules participate in fast and slow axonal transport (Smith, 
1971; Smith et al., 1975; Bird, 1976; Theiss and Meller, 2000). Since 
CGRP is synthesized in the cell body and transported to the sensory 
nerve endings by microtubules (Kashihara et al., 1989), it is possible that 
disruption of microtubules by paclitaxel will interfere with the transport of 
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synaptic vesicles containing CGRP. Indeed, ultrastructural studies showed 
that paclitaxel exposure causes an accumulation of vesicular structures in 
spinal cord and DRG co-cultures reflecting an inhibition of axonal transport 
(Masurovsky et al., 1983). Although I did not measure axonal transport 
directly, I measured CGRP release from central terminals of sensory 
neurons as an indirect index of paclitaxel’s effects on transport of CGRP 
or on the release mechanism. 
Paclitaxel could attenuate CGRP release from sensory endings of 
small diameter fibers by inhibiting the neuropeptide release mechanism. 
There is evidence that microtubules directly participate in the release of 
hormones from secretory cells (Khar et al., 1979). Inhibition of 
microtubules by paclitaxel interferes with stimulated release of 
noradrenalin from chromaffin cells in culture (Thuret-Carnahan et al., 
1985) and with glucose-stimulated insulin release from isolated islets of 
Langerhans (Howell et al., 1982). Furthermore, disruption of microtubules 
by colchicine interferes with the release of neurotrophin-3 from axon 
terminals (Wang et al., 2002).  
It is possible to measure CGRP release in the skin (Kilo et al., 
1997; Kessler et al., 1999; Petho et al., 2004) and from whole DRGs 
(Eberhardt et al., 2008). However, in this study, CGRP release from whole 
DRGs was not examined because the ganglia contain the cell bodies of 
primary afferent neurons where CGRP is synthesized; consequently the 
contribution of microtubule inhibition to decreased release of CGRP 
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cannot be examined. Direct release of CGRP from the skin was not 
examined because CGRP is synthesized and released by endothelial cells 
(Ye et al., 2007; Luo et al., 2008), therefore interpretation of the site of 
release of CGRP in the periphery is difficult. For these reasons, CGRP 
release from central terminals in spinal cord slices was examined. 
The total content of CGRP in the spinal cord of paclitaxel-injected 
animals was not different from vehicle-injected animals. In addition, 
neither 1 nor 2 mg/kg paclitaxel administered every other day for a week, 
altered the KCl or capsaicin-stimulated release of CGRP in spinal cord. 
These data suggest that paclitaxel at these doses does not affect the 
expression nor the transport of CGRP from the cell body to the central 
terminals in the spinal cord.  
The lack of effect of paclitaxel at central terminals may be due to an 
inability of the drug to readily cross the blood brain barrier to enter the 
central nervous system and affect the central endings of the primary 
sensory neurons. Indeed, Cavaletti et al., showed that 5 mg/kg paclitaxel 
injected on day 1, 2, 3, 9 and 10 resulted in the lowest concentrations (11 
ng/g tissue) of the drug in the spinal cord while the concentrations in the 
sciatic nerve and the dorsal root ganglia were 5-fold and 30-fold higher 
respectively (Cavaletti et al., 2000). Therefore, it is likely that the injection 
regimen used in my study does not result in a significant accumulation of 
paclitaxel in the spinal cord. Since sensory neurons have their cell bodies 
in the dorsal root ganglia and a single axon extending from the periphery 
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to the dorsal spinal cord, it is reasonable to expect that any accumulation 
of the drug in the cell body could affect the entire neuron. If the drug was 
affecting the cell bodies, one would expect release to be altered at both 
central and peripheral endings of the neurons. Since I did not observe a 
change in release at the central terminals, it seems likely that paclitaxel 
alters release of CGRP at the peripheral endings of sensory neurons not 
through it’s actions at the cell bodies. 
 
Paclitaxel alters capsaicin-evoked release of CGRP from sensory neurons 
in culture 
To directly assess the effects of paclitaxel on transmitter release 
from sensory neurons and to explore mechanisms that contribute to any 
effects of the drug, sensory neurons in culture as were used as an 
experimental model. In these experiments, the effects of paclitaxel on 
release of CGRP from sensory neurons after exposure to a general 
depolarizing stimulus (30 mM KCl) or to capsaicin were examined. 
Exposure of sensory neurons to 300 nM or 1 µM paclitaxel for 5 
days did not inhibit KCl evoked release of CGRP. However, depending on 
the concentration of paclitaxel used, a biphasic effect of the drug on 
capsaicin-evoked release of CGRP was observed: 10 or 30 nM paclitaxel 
for 5 days increased release of CGRP while 100 nM to 1 µM paclitaxel 
decreased capsaicin-evoked release of CGRP. The altered release was 
not secondary to a change in the total content of the peptide. These data 
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clearly demonstrate that paclitaxel does not interfere with general 
depolarization of sensory neurons or with the neurotransmitter release 
mechanism; it specifically alters (increases or decreases) the ability of 
capsaicin to activate sensory neurons.  
 
Paclitaxel alters gene expression 
Since paclitaxel decreased release of CGRP only when capsaicin 
was used as the evoking stimulus, it is possible that the anti-cancer drug 
alters the expression of the TRPV1 receptor. Indeed paclitaxel at 300 nM 
to 1 µM for 2 to 5 days significantly decreased TRPV1 immunoreactivity in 
isolated sensory neurons. The decreased immunoreactivity was 
secondary to decreased transcription of TRPV1, because mRNA for 
TRPV1 was decreased in paclitaxel-treated neurons. The decrease in 
mRNA occurred at concentrations as low as 30 nM paclitaxel.  
Paclitaxel at 2 mg/kg or 4 mg/kg but not 1 mg/kg decreased the 
mRNA for TRPV1 in DRGs. It must be noted that 2 mg/kg paclitaxel did 
not alter the capsaicin-evoked release of CGRP in spinal cord slices even 
though the mRNA for TRPV1 is decreased. It is possible that when CGRP 
release assays in spinal cord slices were performed (1 week after the last 
injection of paclitaxel), a significant turnover of the TRPV1 receptor had 
not yet occurred. Therefore, even if a small decrease in the 
immunoreactivity of TRPV1 were to be detected, it is possible that residual 
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vanilloid receptors at central terminals is sufficient to cause significant 
increases in Ca2+ influx that is required for neurotransmitter release.  
I also examined if the mRNA expression of Nav1.9 is altered in 
sensory neurons because this ion channel is co-expressed with TRPV1 in 
sensory neurons (Amaya et al., 2006), and its expression has been shown 
to decrease in injured peripheral nerve fibers in neuropathic pain models 
(Decosterd et al., 2002). In isolated sensory neurons exposed to paclitaxel 
(30 nM to 1 µM), I observed a decrease in the mRNA for the voltage-gated 
sodium channel Nav1.9.  
From these data, it can be concluded that the decrease in release 
of CGRP in neurons exposed to 100 nM to 1 µM paclitaxel results from 
decreased expression of TRPV1. However, it must be noted that although 
30 nM paclitaxel for 5 days decreased expression of TRPV1, this 
concentration nonetheless increased capsaicin-evoked release of CGRP. 
Therefore the effects of paclitaxel at lower concentrations do not seem to 
involve expression of TRPV1 since 10 and 30 nM of the drug actually 
sensitize sensory neurons. Paclitaxel actually increases the formation of 
microtubules that are resistant to depolymerization, resulting in depletion 
of tubulin monomers (Letourneau and Ressler, 1984; Roytta et al., 1984; 
Thuret-Carnahan et al., 1985). Thus, it is possible that at lower 
concentrations of the drug all processes that rely on microtubule function 
are enhanced or stimulated, which might explain the increased release of 
CGRP from sensory neurons exposed to the microtubule-inhibiting drug.  
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Paclitaxel decreases the length of neurites 
In studies of other painful neuropathies involving small diameter 
sensory neurons, a decrease in epidermal innervation has been observed 
in skin biopsies (Kennedy and Wendelschafer-Crabb, 1996; Holland et al., 
1997; Kennedy and Wendelschafer-Crabb, 1999; Periquet et al., 1999; 
Polydefkis et al., 2001; Polydefkis et al., 2002; Sommer and Lauria, 2007). 
Furthermore, Bickel et al. showed that in patients with small fiber 
neuropathies, the size of the flare correlates with the nerve fiber count in 
the vicinity of the dermal blood vessels (Bickel et al., 2009). A similar 
decrease in nerve fiber density has been observed in rats injected with 2 
mg/kg paclitaxel every other day for a total of four doses (Siau et al., 
2006). Therefore it is possible that by causing the peripheral endings to 
degenerate paclitaxel decreases innervation of dermal blood vessels, 
resulting in decreased cutaneous vasodilatation in response to capsaicin 
or electrical stimulation.  
Letourneau et al., and Yang et al., independently showed that 
exposure to 700 nM or 30 nM paclitaxel respectively decreased the length 
of already formed neurites of embryonic DRG neurons in vitro (Letourneau 
and Ressler, 1984; Yang et al., 2009). Therefore, inhibition of neurite 
degeneration or treatments that promote regeneration are strategies that 
can be used to prevent or reverse peripheral nerve damage by paclitaxel. 
Indeed Melli et al., showed that recombinant human erythropoietin 
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prevented paclitaxel-induced distal degeneration in vitro and loss of 
sensory nerve fibers from the epidermal layer in vivo (Melli et al., 2006).  
In order to examine mechanisms contributing to neurite 
degeneration, I established a model to examine the effects of paclitaxel on 
neurites in isolated sensory neurons. Individual cells were injected with 
gold particles that were previously coated with the cDNA for EGFP 
according to the method described by Dib-Hajj et al., (Dib-Hajj et al., 
2009). In this way I could visualize individual neurons expressing EGFP 
and measure the length of their neurites after addition of drug. The 
velocity at which particles were injected into individual neurons was 
previously optimized so that the use of gold particles did not result in 
either death or degeneration of neurons. The neurons expressing EGFP 
were allowed to grow in culture for 7 days before exposure to the anti-
cancer drug. Paclitaxel (100 to 300 nM) causes decrease in the length of 
the neurites. This decrease cannot be attributed to the stress induced by 
injecting gold particles because it is possible to record whole cell currents 
and action potentials about 48 hours after transfection by this method 
(Dib-Hajj et al., 2009).  
While many investigators examined the effects of the microtubule-
stabilizing drug on initiation of neurite outgrowth (Konings et al., 1994; 
Hayakawa et al., 1998; Hayakawa et al., 1999; Scuteri et al., 2006), very 
few studies examine the effects of paclitaxel on length of already 
established neurites (Letourneau and Ressler, 1984; Melli et al., 2006; 
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Yang et al., 2009). Yang et al., observed an approximately 25% decrease 
in axonal length after a 24 hour exposure to 30 nM paclitaxel. In my study 
a 25% decrease was observed when sensory neurons were exposed to a 
higher dose (100 µM paclitaxel) for a longer time (5 days). Such a 
discrepancy can be explained by the fact that my work examines the 
effects of paclitaxel on adult DRG neurons; whereas all other studies in 
the literature were performed on embryonic neurons. Yang and coworkers 
made an interesting observation that application of paclitaxel only to axons 
in a compartmentalized culture system resulted in their degeneration while 
addition of the drug to the compartment containing cell bodies did not 
cause shortening of neurites. This observation suggests that inhibition of 
axonal microtubules resulting in decreased delivery of nutrients and other 
molecules required for axonal growth and maintenance contributes to the 
degeneration of neurites (Yang et al., 2009). Furthermore, there is 
evidence that paclitaxel affects mitochondrial function (Andre et al., 2002; 
Kidd et al., 2002; Flatters and Bennett, 2006; Jin et al., 2008). 
Mitochondria are highly concentrated at synapses and at the tip of growth 
cones where they are important for providing energy for neurotransmitter 
release and sequestration of calcium at synaptic sites. Therefore, it is 
possible that paclitaxel-induced mitochondrial damage leads to axonal 
degeneration due to disruption of calcium homeostasis or lack of energy 
production required for axon growth and maintenance.  
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Relevance of in vivo and in vitro observations 
There is an apparent inconsistency between the paclitaxel-induced 
hypersensitivity demonstrated by Polomano et al., and Weng et al., 
(Polomano et al., 2001; Weng et al., 2005) and my data demonstrating a 
decrease in sensory neuron mediated blood flow. Hypernociception is 
often attributed to hyperexcitability of sensory neurons, while decreased 
blood flow after activation of sensory neurons suggests a loss of function 
of sensory neurons. The question thus arises: how could diminished 
release of neurotransmitter from sensory neurons result in 
hypernociception? It is possible that changes in nociceptive behavior 
observed by others is a result of changes in function of neurons in the 
central nervous system as a result of central sensitization (Polomano et 
al., 2001; Weng et al., 2005). Central sensitization is the increased 
activation of synapses in the dorsal spinal cord due to repeated 
stimulation of the primary afferent sensory neurons. The possibility that 
paclitaxel administration results in central sensitization is supported by the 
observation by Weng et al., that the dosing regimen I used (1mg/kg, 4 
times a week) decreases glutamate transporters in the dorsal spinal cord 
(Weng et al., 2005). Furthermore, the wide dynamic range (WDR) neurons 
in the spinal cord from paclitaxel-treated animals have an increase in 
spontaneous activity, an increase in after-discharges in response to 
mechanical and thermal stimuli and an increase in wind-up in response to 
cutaneous stimuli (Cata et al., 2006a).  
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Increased presynaptic and/or postsynaptic excitability could 
contribute to the increased firing of neurons in the central nervous system 
(Woolf, 2007; Seybold, 2009; Stein et al., 2009). Therefore, an increase in 
capsaicin-evoked release of CGRP in the spinal cord of paclitaxel-injected 
animals might account for the paclitaxel-induced increase in spontaneous 
activity of WDR neurons. However, paclitaxel (1 or 2 mg/kg) did not alter 
capsaicin-evoked release of CGRP from central terminals of primary 
afferent sensory neurons. A possible explanation is that in my studies 
release from spinal cord slices was measured one week after the last 
injection of paclitaxel. Therefore it is possible that an increase in 
transmitter release leading to central sensitization might occur earlier in 
the dosing schedule. Thus, it is important in future studies to examine 
release of CGRP in the spinal cord of paclitaxel injected animals at earlier 
time points to determine if its release is enhanced during the initial stages 
of the dosing regimen. Furthermore, I only examined the function of a 
subset of nociceptive neurons (only the peptidergic neurons) in paclitaxel 
injected animals. It is known that paclitaxel affects all types of sensory 
neurons, therefore it is possible that the drug has differential effects on 
non-peptidergic sensory neurons. Further experiments are necessary to 
examine if paclitaxel alters the release of glutamate in spinal cord 
perfusate from paclitaxel-injected animals.  
Another explanation for increased sensitivity in the skin of 
paclitaxel-injected animals is that attenuated vasodilatation results in 
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peripheral ischemia resulting in high proton concentrations in the 
periphery. In ischemic conditions, pH levels as low as 5.4 has been 
measured (Steen et al., 1992; Steen and Reeh, 1993) and Issberner et al., 
showed that in experimental subjects, decreased intradermal pH directly 
correlates with increased pain perception (Issberner et al., 1996). The link 
between low pH and pain has been made by the discovery of molecular 
transducers expressed on sensory neurons, namely TRPV1 (Fischer et 
al., 2003; Caterina, 2007) and those belonging to the ASIC family, which 
respond to high extracellular proton concentration (Krishtal and 
Pidoplichko, 1981a; Krishtal, 2003). Protons have the ability to not only 
sensitize sensory neurons to non-noxious stimuli via their actions on 
TRPV1 and ASICs, but they can also directly activate these channels to 
transduce pain stimuli. Therefore, the sensitization of nociceptors as a 
result of peripheral ischemia might help explain another symptom of 
neuropathy - the paradoxical burning pain that patients experience when 
their skin is exposed to cold temperatures (Dougherty et al., 2004). In 
healthy individuals, exposure to cold temperatures results in 
vasoconstriction and a consequent decrease in skin blood flow. This 
vasoconstriction is balanced by reflex vasodilatory mechanisms in which 
sensory neurons have been proposed to play an important role (Bunker et 
al., 1990; Terenghi et al., 1991). Therefore, It is possible that in 
pathological situations where sensory neuron mediated vasodilatation is 
absent, vasoconstriction induced by cold temperatures is prolonged, 
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therefore leading to ischemia and subsequent activation of proton 
sensitive channels on nociceptive neurons to evoke sensations like 
burning and tingling (Krishtal and Pidoplichko, 1981a, b; Steen et al., 
1992).  
Burning pain is also associated with many other small fiber painful 
neuropathies such as diabetic neuropathy, human immunodeficiency 
virus-associated sensory neuropathies, neuropathies secondary to anti-
retroviral drugs, and post-herpetic neuralgia (Tavee and Zhou, 2009). 
Decreased sensory neurons mediated cutaneous vasodilatation been 
observed in patients with diabetic neuropathy (Forst et al., 1997; Pitei et 
al., 1997; Hamdy et al., 2001; Caselli et al., 2003; Kramer et al., 2004; 
Caselli et al., 2006; Khalil et al., 2007; Quattrini et al., 2007). More 
importantly, a direct link between decreased cutaneous vasodilatation and 
pain can be seen in the study by LeVasseur et al; they observed 
decreased capsaicin-evoked vasodilatation at skin sites where pain was 
experienced by elderly patients with post herpetic neuralgia, while normal 
(non-painful) skin sites demonstrated normal responses to capsaicin 
injection (LeVasseur et al., 1990). Furthermore, decreased CGRP 
mediated vasodilatation has been postulated to be a contributing factor to 
the pathology of Raynaud’s phenomenon, a condition which is 
characterized by chronic digital pain following exposure to cold 
temperatures (Brain et al., 1990). Therefore my observation of decreased 
cutaneous vasodilatation in paclitaxel-injected animals is in agreement 
	   	   	   	   	   159 
with similar observations made in other neuropathies that are 
characterized by burning pain. 
Neurogenic control of skin blood flow is important for temperature 
regulation of the skin (Roosterman et al., 2006); in patients with diabetic 
and hereditary autonomic neuropathy, a dysregulation of skin temperature 
has been observed (Kitaoka et al., 1989; Polo et al., 2000). Therefore, it is 
possible that decrease in cutaneous vasodilatation might explain the 
coldness in the extremities experienced by patients receiving 
chemotherapy with paclitaxel as is observed in patients with complex 
regional pain syndrome and Raynaud’s phenomenon (Bunker et al., 1990; 
Dougherty et al., 2004). Clearly, examination of blood flow is not only an 
important endpoint for the study of sensory neurons in this study, but 
changes in vasodilatation occurring secondary to peripheral neuropathy 
could account for at least some of the sensory abnormalities experienced 
by patients.  
My observation that paclitaxel decreased the length of neurites of 
sensory neurons coupled with the finding by Siau et al., that 
intraepidermal nerve fiber density is decreased in paclitaxel injected 
animals could explain the decreased vasodilatation observed in paclitaxel 
injected animals (Siau et al., 2006). Bickel et al., observed a direct 
correlation between density of nerve endings in the skin and electrical 
stimulation-induced vasodilatation in patients with neuropathy (Bickel et 
al., 2009). A possible explanation for this correlation is that retraction of 
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nerve endings could decrease sensory innervation of dermal blood 
vessels and remove CGRP from the nerve muscle synapse, thus reducing 
the effectiveness of CGRP release from free nerve endings in producing 
neurogenic vasodilatation. Further studies are therefore warranted to 
examine the mechanisms that mediate neurite retraction so that effective 
strategies to preserve the integrity of sensory neurons may be devised. 
Another interesting and novel contribution of this study was the 
observation that paclitaxel’s effects on CGRP release is biphasic, i.e. 
increased CGRP release at exposure to 10 and 30 nM paclitaxel and 
decreased release occurring at 100 nM to 1 µM paclitaxel. The increased 
release observed with lower concentrations of paclitaxel is consistent with 
the hypersensitivity to noxious stimuli observed in animals that receive 
multiple injections of lower doses (e.g.1 mg/kg) paclitaxel. The decrease in 
CGRP release observed at higher concentrations of paclitaxel is in 
agreement with the loss of sensitivity to thermal and mechanical stimuli 
that is observed at multiple injections of higher concentrations of paclitaxel 
(e.g. 16 mg/kg) in animal models. Furthermore, many patients experience 
pain following the first cycle of infusion of paclitaxel (250 mg/m2), which 
often subsides within a week (Wiernik et al., 1987a; Lipton et al., 1989; 
Sahenk et al., 1994). Loprinzi et al., speculated that this acute pain 
sensation experienced in the initial stages of chemotherapy is a result of 
sensitization of nociceptive neurons (Loprinzi et al., 2007). With 
successive cycles of administration of paclitaxel, the symptoms are further 
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exaggerated and increased in duration. Gradually the symptoms evolve to 
loss of sensation evidenced by increased thermal and vibratory thresholds 
(Lipton et al., 1989). Therefore, my observations on effects of paclitaxel on 
capsaicin-evoked CGRP release from isolated sensory neurons correlates 
well with behavioral studies in animals and symptoms experienced by 
patients undergoing chemotherapy with the drug. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 The experiments conducted as part of this thesis has provided a 
better understanding of the mechanisms that mediate the sensory 
disturbances after treatment with paclitaxel than what is currently known. 
The current study demonstrates that administration of paclitaxel causes a 
decrease in the release of CGRP from peripheral terminals of sensory 
nerves, and from sensory neurons in culture. Furthermore, in isolated 
sensory neurons paclitaxel causes degeneration of neurites, which might 
be a mechanism to account for the decrease in peripheral blood flow 
observed in animals and the burning pain and coldness in extremities 
experienced by patients. Therefore, whether the symptoms of peripheral 
neuropathy resolve or persist depends on the extent of damage to sensory 
neurons. It is important to identify the factors that mediate long-term 
changes in sensory neuron function.  
One possible mechanism by which paclitaxel produces neurotoxic 
effects is via mitochondrial damage. In neuroblastoma cells, paclitaxel (1 - 
100 µM) causes mitochondrial swelling, induces opening of the 
mitochondrial permeability transition pore (mPTP) and cytochrome 
release (Andre et al., 2000; Andre et al., 2002) and mitochondrial swelling 
in the saphenous nerve of rats chronically treated with paclitaxel (Flatters 
and Bennett, 2006). By damaging mitochondria paclitaxel can cause 
altered calcium homeostasis (Siau and Bennett, 2006) and increased 
production of free radicals (Andre et al., 2002; Wang et al., 2004; Fawcett 
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et al., 2005; Ramanathan et al., 2005; Alexandre et al., 2006; Alexandre 
et al., 2007; Kim et al., 2008). It must be noted that free radicals at 
moderate concentrations are harmless and are eliminated by cellular anti-
oxidants. When free radicals accumulate to high concentrations, they can 
damage major cell constituents by oxidizing proteins and targeting them 
for proteolysis, oxidizing DNA and in doing so altering gene expression, 
and inducing lipid peroxidation resulting in increased membrane 
permeability and cell death (Sevanian and Hochstein, 1985; Richter, 
1987). Therefore, experiments are warranted to examine mitochondrial 
function and measurement of free radicals after exposure of isolated 
sensory neurons to paclitaxel. Furthermore, the role of anti-oxidants in 
prevention of neurite degeneration must also be examined.  
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